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Abstract
Factors that influence variation in clinical decision-making
about thrombolysis in the treatment of acute ischaemic
stroke: results of a discrete choice experiment
Richard G Thomson,1* Aoife De Brún,1 Darren Flynn,1 Laura Ternent,1
Christopher I Price,2,3 Helen Rodgers,2,3 Gary A Ford,4
Matthew Rudd,2,3 Emily Lancsar,5 Stephen Simpson6 and John Teah6
1Institute of Health and Society, Newcastle University, Newcastle upon Tyne, UK
2Stroke Unit, Wansbeck General Hospital, Northumbria Healthcare NHS Foundation Trust,
North Shields, UK
3Institute of Neuroscience (Stroke Research Group), Newcastle University, Newcastle upon
Tyne, UK
4Oxford University Hospitals NHS Trust, Oxford, UK
5Centre for Health Economics, Monash University, Melbourne, VIC, Australia
6The Stroke Association, Gateshead, UK
*Corresponding author Richard.Thomson@newcastle.ac.uk
Background: Intravenous thrombolysis for patients with acute ischaemic stroke is underused (only 80%
of eligible patients receive it) and there is variation in its use across the UK. Previously, variation might have
been explained by structural differences; however, continuing variation may reflect differences in clinical
decision-making regarding the eligibility of patients for treatment. This variation in decision-making could
lead to the underuse, or result in inappropriate use, of thrombolysis.
Objectives: To identify the factors which contribute to variation in, and influence, clinicians’ decision-making
about treating ischaemic stroke patients with intravenous thrombolysis.
Methods: A discrete choice experiment (DCE) using hypothetical patient vignettes framed around areas of
clinical uncertainty was conducted to better understand the influence of patient-related and clinician-related
factors on clinical decision-making. An online DCE was developed following an iterative five-stage design
process. UK-based clinicians involved in final decision-making about thrombolysis were invited to take part via
national professional bodies of relevant medical specialties. Mixed-logit regression analyses were conducted.
Results: A total of 138 clinicians responded and opted to offer thrombolysis in 31.4% of cases. Seven
patient factors were individually predictive of the increased likelihood of offering thrombolysis (compared
with reference levels in brackets): stroke onset time of 2 hours 30 minutes (50 minutes); pre-stroke
dependency modified Rankin Scale score (mRS) of 3 (mRS4); systolic blood pressure (SBP) of 185 mmHg
(140 mmHg); stroke severity scores of National Institutes of Health Stroke Scale (NIHSS) 5 without aphasia,
NIHSS 14 and NIHSS 23 (NIHSS 2 without aphasia); age 85 years (65 years); and Afro-Caribbean (white).
Factors predictive of not offering thrombolysis were age 95 years; stroke onset time of 4 hours 15 minutes;
severe dementia (no memory problems); and SBP of 200 mmHg. Three clinician-related factors were
predictive of an increased likelihood of offering thrombolysis (perceived robustness of the evidence for
thrombolysis; thrombolysing more patients in the past 12 months; and high discomfort with uncertainty)
and one factor was predictive of a decreased likelihood of offering treatment (clinicians’ being comfortable
treating patients outside the licensing criteria).
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Limitations: We anticipated a sample size of 150–200. Nonetheless, the final sample of 138 is good
considering that the total population of eligible UK clinicians is relatively small. Furthermore, data from the
Royal College of Physicians suggest that our sample is representative of clinicians involved in decision-making
about thrombolysis.
Conclusions: There was considerable heterogeneity among respondents in thrombolysis decision-making,
indicating that clinicians differ in their thresholds for treatment across a number of patient-related factors.
Respondents were significantly more likely to treat 85-year-old patients than patients aged 68 years and
this probably reflects acceptance of data from Third International Stroke Trial that report benefit for
patients aged > 80 years. That respondents were more likely to offer thrombolysis to patients with severe
stroke than to patients with mild stroke may indicate uncertainty/concern about the risk/benefit balance in
treatment of minor stroke. Findings will be disseminated via peer-review publication and presentation at
national/international conferences, and will be linked to training/continuing professional development
(CPD) programmes.
Future work: The nature of DCE design means that only a subset of potentially influential factors could
be explored. Factors not explored in this study warrant future research. Training/CPD should address the
impact of non-medical influences on decision-making using evidence-based strategies.
Funding: The National Institute for Health Research Health Services and Delivery Research programme.
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Plain English summary
Intravenous thrombolysis (blood thinner or ‘clotbuster’) is an effective emergency treatment for patientswith a stroke due to a clot which blocks a blood vessel in the brain. Although this is recommended
for carefully selected patients, treatment rates vary across the UK. Since the introduction of ‘24/7’ stroke
services (services available 24 hours per day, 7 days per week), continuing differences may represent
differences in clinicians’ decision-making on patients’ suitability for treatment. Decision-making is complex,
owing to the emergency context of the decision (treatment must be given within 4.5 hours of symptom
onset) and the many factors that influence the levels of benefit/risk for patients. These differences in
decision-making could result in undertreatment or in the inappropriate treatment of patients who do not
meet treatment criteria.
We conducted a study describing hypothetical patients with different characteristics [e.g. age, gender,
seriousness of symptoms using the National Institutes of Health Stroke Scale (NIHSS)] to understand
which characteristics influence doctors’ decision-making. We found that patients with the following
characteristics were more likely to be offered thrombolysis (compared with reference levels in brackets):
stroke onset time of 2 hours 30 minutes (50 minutes); moderate pre-stroke dependency on others
(moderate to severely dependent); systolic blood pressure of 185 mmHg (140 mmHg); higher stroke
severity scores (NIHSS 2 without aphasia); age 85 years (65 years); and Afro-Caribbean (white). Factors
linked with the decision not to offer treatment were age 95 years; symptom onset time of 4 hours
15 minutes; severe dementia (compared with no memory problems); and systolic blood pressure of
200 mmHg. Three clinician-related characteristics were linked with an increased likelihood of offering
treatment (perceived strength of the evidence for the treatment; treating more patients in the past
12 months; and high discomfort with uncertainty) and one characteristic was linked to a decreased
likelihood of offering treatment (comfort treating patients outside treatment criteria).
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Scientific summary
Background
Intravenous thrombolysis using recombinant tissue plasminogen activator is an effective medical treatment
for patients with acute ischaemic stroke. Despite clear evidence of its efficacy and benefit in certain patient
groups and presence in national guidelines, it is underused, as only approximately 80% of patients eligible
for thrombolysis receive it in the UK. As thrombolysis treatment can reduce disability from stroke and
consequent care costs, maximising its appropriate use is a health and economic priority. Previously, the
suboptimal use of thrombolysis might have been largely attributable to structural factors; however, with
the widespread implementation of ‘24/7’ hyperacute stroke services (services available 24 hours per day,
7 days per week), continuing variation is likely to reflect differences in clinical decision-making, in particular
the influence of ambiguous areas in the guidelines, licensing criteria and research evidence. This variation
in decision-making could lead to the underuse, or result in inappropriate use, of thrombolysis.
Objectives
This research sought to elucidate factors influencing thrombolysis decision-making by using (1) patient
vignettes (designed to explore difficult cases both within and outside the licensing criteria) to identify
patient-related and clinician-related factors that may help to explain variation in treatment; and
(2) associated trade-offs in decision-making based on the interplay of factors influencing decision-making.
The study aimed to influence clinicians’ behaviour by translating learning into continuing professional
development (CPD) activity, national clinical guidelines, supporting implementation of an existing
thrombolysis decision support tool and informing clinical audit and evaluation programmes (Sentinel Stroke
National Audit Programme; SSNAP).
Methods
A discrete choice experiment (DCE) framed around areas of clinical uncertainty was conducted to better
understand how clinicians make decisions about whether or not to offer thrombolysis to patients with
acute ischaemic stroke. To inform the design of the DCE, a five-stage process was undertaken to ensure
that all potentially influential factors were considered for inclusion; to gain insights into the ‘grey areas’ of
the licensing criteria with reference to levels of patient factors; to maximise clinical face validity; and to
ensure that the content was meaningful and sufficient for clinicians to reach a decision about the offer of
thrombolysis. A fractional factorial design was employed to combine levels of patient factors in vignettes,
which were presented to clinicians to allow estimation of the variable effects on decisions to offer
thrombolysis. Participants were recruited via e-mails and newsletters circulated via the professional bodies
representing the various medical specialties involved in acute stroke care, as well as via the Stroke
Association Stroke Improvement Bulletin and a notice about the study on the SSNAP website. Mixed-logit
regression analyses were conducted on the data.
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Results
A total of 138 clinicians responded and, overall, opted to offer thrombolysis in 31.4% of cases. Seven
patient factors were individually predictive of increased likelihood of offering thrombolysis (compared with
reference levels in brackets): stroke onset time of 2 hours 30 minutes (50 minutes); pre-stroke dependency
modified Rankin Scale (mRS) score of 3 (mRS4); systolic blood pressure (SBP) of 185 mmHg (140 mmHg);
stroke severity [using National Institutes of Health Stroke Scale (NIHSS)] scores of NIHSS 5 without aphasia,
NIHSS 14 and NIHSS 23 (NIHSS 2 without aphasia); age 85 years (65 years); and Afro-Caribbean (white).
Factors predictive of not offering thrombolysis were age 95 years; stroke onset time of 4 hours 15 minutes;
severe dementia (no memory problems); and SBP of 200 mmHg. Three clinician-related factors were
predictive of an increased likelihood of offering thrombolysis (perceived robustness of the evidence for
thrombolysis; thrombolysing more patients in the past 12 months; and high discomfort with uncertainty)
and one factor was predictive of a decreased likelihood of offering treatment (clinicians’ being comfortable
with treating patients outside the licensing criteria).
Limitations
Although we sought a sample size of 150–200 participants, our final sample of 138 is good, as the total
population of eligible clinicians in the UK is relatively small. Furthermore, census data from the Royal
College of Physicians suggest that our sample is representative of UK-based clinicians involved in final
decisions about thrombolysis. A limitation of the study was that trade-offs between factors could not be
explored, as no linear variables were included in the analysis.
Conclusions
There was considerable heterogeneity among respondents in thrombolysis decision-making (in the context
of cases which were specifically generated to address grey areas/areas of uncertainty), indicating that
clinicians differ in their thresholds for treatment across a number of patient-related factors. Respondents
were significantly more likely to treat 85-year-olds than patients aged 68 years and this likely reflects
acceptance of data from the Third International Stroke Trial that report benefit for patients aged > 80 years,
in particular for those with onset-to-treatment time of < 3 hours, and recognition that chronological age
does not necessary equate to physiological age. The findings suggest that clinicians may be willing to delay
treatment for patients who present early. This may reflect clinicians’ inexperience, given the infrequent
nature of early presentation. Alternatively, some clinicians may wait a short while to see if the symptoms
spontaneously improve or to give blood pressure time to stabilise. The former explanation is counter to the
evidence for better outcomes with earlier treatment.
The finding that participants were significantly more likely to offer thrombolysis to patients with severe
stroke and to not offer thrombolysis to patients with mild stroke may indicate uncertainty or concern
about the risk/benefit balance around the benefit of treatment of minor stroke or concerns that
symptomatic intracranial haemorrhage is not an acceptable risk for those with less severe symptoms. There
was significant heterogeneity among respondents on the influence of NIHSS 2 with aphasia and NIHSS 5
without aphasia. This implies that clinicians differ in their thresholds for treatment of minor stroke and that
they may consider the gains in quality of life for individual patients with isolated language difficulties to be
of less value.
SCIENTIFIC SUMMARY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xxii
Future work
Evidence-based strategies such as cognitive debiasing approaches and the use of decision support tools
could be incorporated within clinical training, CPD and masterclasses. Problem-based learning using a
representative cross-section of patients with different clinical and non-clinical characteristics, which reflects
up-to-date observational and trial evidence, has the potential to maximise the appropriate delivery of
thrombolysis in the treatment of acute ischaemic stroke.
The nature of DCEs demands that only a subset of potentially influential factors on clinical decision-making
could be explored, although these were carefully selected via a rigorous design process. Factors not
explored in this study warrant future research to understand their impact on the clinical decision to
offer intravenous thrombolysis. These include the influence of decision support tools and/or graphical
depictions of the likely balance of absolute risks and benefits for individual patients treated with and
without thrombolysis.
Funding
Funding for this study was provided by the Health Services and Delivery Research programme of the
National Institute for Health Research.
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Chapter 1 Introduction
Overview of the research
This research involved the design and development of a discrete choice experiment (DCE) to explore
the patient-related and clinician factors that influence clinical decision-making regarding the offer of
intravenous thrombolysis for patients with acute ischaemic stroke. This chapter provides a synopsis of the
context and the rationale for the study, including the study aims and details of the project team.
Context and rationale for the research
Stroke remains one of the leading causes of death and disability in the UK.1 Thrombolysis with recombinant
tissue plasminogen activator (rtPA) with alteplase is a cost-effective treatment for acute ischaemic stroke
but unwarranted variation exists in use of thrombolysis in the UK, despite the existence of the National
Stroke Strategy,1 National Institute for Health and Care Excellence (NICE) guidelines,2 treatment licensing
criteria3 and a strong evidence base.2,4–6 Since the expansion of ‘24/7’ hyperacute stroke services (i.e.
services available 24 hours per day, 7 days per week), structural factors, such as access to treatment and
computed tomography (CT) investigation, are less likely to explain this variation. Hence remaining variation
is more likely to be accounted for by differences in clinical decision-making about offering thrombolysis,
based on interpretation and understanding of patient variables, and on variables relating to the individual
decision-makers (such as experience or attitude towards risk). The current study captured information on
which patient and clinician factors influence clinicians’ willingness to offer intravenous thrombolysis to
ischaemic stroke patients, as well as determining their impact on decision-making. By understanding how
clinicians internally and externally negotiate the risks and benefits in different patients, we can optimise
appropriate use of thrombolysis and better support risk communication, consent and decision-making with
patients. Outcomes of the research will include benefits for service delivery by (1) translating learning into
training and continuing professional development (CPD); (2) supporting the implementation of a decision
support tool that has been developed to support decision-making in thrombolysis; and (3) informing
the content and interpretation of audit and evaluation programmes.
Aims and objectives
This study aimed to identify the factors that contribute to variation in, and influence, clinicians’ decision-making
about intravenous thrombolysis for acute ischaemic stroke, in order to inform programmes that seek to
influence clinical behaviour and decision-making.
This study had four specific research objectives:
1. to determine which patient factors influence clinical decision-making about the offer of thrombolysis
2. to identify and quantify the trade-offs clinicians make regarding the decision to offer thrombolysis
3. to determine which clinical factors influence clinical decision-making about the offer of thrombolysis
(e.g. clinician experience, setting, personality type)
4. to influence clinicians’ behaviour by translating learning into CPD activity, national clinical guidelines,
supporting implementation of an existing thrombolysis decision support tool and informing clinical audit
and evaluation programmes [e.g. Sentinel Stroke National Audit Programme (SSNAP)].
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The study captured information on medical judgement and choice by undertaking a DCE. A DCE is an
approach that facilitates the consideration of multiple factors in a decision, and therefore is an appropriate
and valuable technique to explore the complex clinical decision of the offer of thrombolysis for patients
with acute ischaemic stroke. This approach also allows for investigation of the impact of clinician factors,
such as attitude to risk and level of experience, on decision-making. The DCE approach offers a means
through which the nuances of decision-making, not easily accessed through other more traditional
research methods, can be understood. DCEs have been increasingly adopted to examine decision-making
in areas of health care including stroke rehabilitation.7,8
This study involved two key components:
1. a five-stage iterative process to develop and design a clinically valid DCE
2. administration of the DCE.
Project team
The Project Management Group consisted of three stroke clinical researchers, one trainee stroke physician,
two patient representatives (from the Stroke Association), two chartered psychologists, two health
economists, an expert in shared decision-making and the project secretary. This group met on average
once per month during the course of the project to discuss all aspects of the research.
An external advisory group met on three occasions during the course of the study. This group included the
members of the Project Management Group and Professor Anthony Rudd (Professor of Stroke Medicine,
King’s College London, who chaired the group), Ms Chucks Golding (patient representative), Dr Dean Shipsey
(Emergency Medicine Consultant, Northumbria Healthcare NHS Trust), Ms Elizabeth Morris (Stroke Network
Delivery Manager, NHS) and Professor Tim Coats (Professor of Emergency Medicine, University of Leicester).
The function of the advisory group was to provide feedback and advice, and review progress on all aspects of
the study.
Ethical approval
Ethical approval for this study was obtained from the Newcastle University Research Ethics Committee
(reference 00720/2013). All potential participants were provided with information about the study and
they had an opportunity to address questions to the researchers prior to participation. Individuals were
informed that their participation was entirely voluntary and that they were free to withdraw at any time
without reason. In the online DCE survey, an information screen preceded the survey, which included a
brief study description, and participants were made aware that their consent was implied through
completion of the survey. All personal identifiers were removed to protect confidentiality.
Structure of the report
Chapter 2 presents the background to the research in terms of an overview of the literature, including a
summary of the literature on the clinical decision-making that has informed the design of the current
study. Chapter 3 details the methods adopted in designing the study and the rationale for the use of a
DCE. Chapter 3 also outlines the five-stage systematic process undertaken to design the DCE used in the
current research, along with details on participant sampling, data management and the analysis. Chapter 4
describes the sample profile and the results of the DCE in terms of levels of patient and clinician factors
that were identified as statistically significant predictors of thrombolysis decision-making. Chapter 5
discusses the results of the DCE in the context of the existing literature and offers recommendations for
stroke training and further research. Finally, Chapter 6 summarises the conclusions that can be drawn from
the research and offers suggestions for future work.
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Chapter 2 Background
S troke is a leading cause of death and disability; there are approximately 152,000 strokes in the UKevery year and between 80% and 85% of these are ischaemic strokes.9 Ischaemic strokes are caused
by a blockage in a blood vessel supplying blood to the brain. This can halt blood flow, resulting in damage
to the brain and a loss of function.
Context of the study: acute ischaemic stroke and
intravenous thrombolysis
Intravenous thrombolysis using rtPA is an effective medical treatment for patients with acute ischaemic
stroke. Despite its inclusion in national guidelines and evidence of its benefit in certain patient
groups,5,6,10,11 it is underused, as recent estimates from SSNAP suggest that one in five patients eligible for
intravenous thrombolysis does not receive it.12,13 As thrombolytic treatment can reduce disability from
stroke and resulting care costs,10 maximising its appropriate use is a health and economic priority.
Although there are national guidelines for treatment,2 the clinical decision regarding the offer of
thrombolysis for patients is complex and multifactorial. The time-limited window for treatment (within
4.5 hours of symptom onset), the emergency context of the decision, potential difficulties in engaging
patients and carers in decision-making and obtaining consent and the many clinical factors that might
influence the balance between risk and benefit for individual patients further complicate the decision.14
Early treatment of patients with acute ischaemic stroke with thrombolysis is associated with more
favourable outcomes,15 yet there is a small but significant risk of adverse outcomes as a result of
treatment.16 Thrombolytic treatment may result in adverse effects, such as systemic bleeding, angioedema17
and symptomatic intracranial haemorrhage (sICH), which is the most disabling and potentially fatal
complication, occurring in approximately 3–4% of patients.12 By definition, sICH usually results in worse
disability than would have occurred without thrombolytic treatment and in a small proportion of patients
can be responsible for death.18
Decision-making may be further complicated by areas of uncertainty in research evidence, typically where
high-quality empirical data do not exist regarding the suitability of certain patients for thrombolysis, for
example patients with dementia or older patients.14,17 Given the recorded variation in thrombolysis
treatment rates,19 the lack of expert consensus on several exclusion criteria for treatment (such as recent
medical procedures and spontaneous improvement rate)20 and the ongoing debates regarding the efficacy
of thrombolysis,21–26 it is important to understand factors which influence clinicians’ decisions about
whether or not to give intravenous thrombolysis to patients with acute ischaemic strokes, using a method
that reflects decision-making in practice.27,28
Trial evidence and guidelines on intravenous thrombolysis
A meta-analysis of data from 6756 individual patient data combined from nine randomised trials was
recently conducted to explore the effect of treatment delay, patient age and stroke severity on the effects
of thrombolysis in acute stroke.15 The analysis confirmed that thrombolysis increased the likelihood of a
good outcome and that earlier treatment was associated with greater patient benefit and outcomes.15 This
work presented strong evidence of the benefit of thrombolysis (compared with placebo groups) up to
4.5 hours post symptom onset. Significantly, the analysis also revealed proportional treatment benefits that
were similar irrespective of age or stroke severity. An increased risk of sICH was observed for the treatment
group and was similar irrespective of treatment delay, age or stroke severity. However, those with more
severe strokes had the greatest absolute risk of sICH.
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The evidence underlying this meta-analysis was drawn from major clinical trials of thrombolysis (with
alteplase) conducted since the 1990s: the European Cooperative Acute Stroke Study (ECASS) trials
(ECASS-I, -II and -III),29,30 the National Institute of Neurological Disorders and Stroke (NINDS) trial,31 the
Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischaemic Stroke (ATLANTIS) trial32 and
the Third International Stroke Trial (IST-3).5
The first ECASS29 trial randomised over 600 patients presenting within 6 hours of symptom onset to
placebo or treatment groups. Although no significant differences emerged between the groups, post-hoc
analyses demonstrated that, if protocol violations were removed, results indicated a benefit of treatment
with thrombolysis (improved functional and neurological outcomes for patients with moderate to severe
neurological deficit).
In contrast to ECASS, NINDS31 randomised patients presenting within a shorter onset time: 3 hours from
symptom onset. The NINDS study had two parts and two primary aims: the first tested if thrombolysis
resulted in patient improvement in terms of an positive change of ≥ 4 points on the NIHSS (measuring
neurological impairment) within 24 hours; and the second assessed whether or not there was a significant
and consistent difference between the treatment and placebo groups in terms of the proportion of
patients who recovered with minimal or no deficit 3 months post treatment (using a global statistic
comprising four different outcome measures).31 In part 1, no significant differences were observed, but
post-hoc tests revealed improvement in the treatment group in most time periods, compared with placebo.
In part 2, compared with the placebo group, thrombolysis was found to have a significant positive benefit
on patient outcome measures. The NINDS trial concluded that, although an increased incidence of sICH
was observed, treatment with intravenous thrombolysis within 3 hours of symptom onset improved patient
outcomes at 3 months.
The second ECASS trial (ECASS-II30) again explored treatment with thrombolysis within an extended time
window of up to 6 hours post symptom onset. The majority of enrolled patients were treated within
the 3- to 6-hour time window and no significant differences emerged between the placebo and the
treatment groups.
In the same period, the ATLANTIS32 trial explored the effect of administration of thrombolysis when
symptom onset was between 3 and 5 hours. The results indicated no significant differences between
the groups.
Following the completion of these trials, a pooled analysis of all trial data was conducted.16 This revealed a
significant positive effect of thrombolysis and highlighted the importance of treating patients as early as
possible after symptom onset. A statistically significant treatment effect was present between 3 and
4.5 hours from symptom onset, but not between 4.5 and 6 hours.16 It was concluded that patient
outcomes are enhanced the earlier thrombolysis is administered, with a potential benefit after 3 hours,
but with increased risk of adverse events.
The ECASS-III33 trial included over 800 patients randomised to treatment or placebo group within
3–4.5 hours of symptom onset. The trial confirmed the significant benefit of thrombolysis over placebo in
terms of patient outcomes when treatment was administered within 3–4.5 hours post symptom onset.
The results also found a higher risk of sICH in the treatment group.
Current UK NICE guidelines2 recommend intravenous thrombolysis with alteplase for treating patients with
acute ischaemic stroke in adults if treatment is started as early as possible within 4.5 hours of the onset
of stroke and when intracranial haemorrhage has been excluded by imaging techniques. The NICE
Technology Appraisal Committee concluded that intravenous thrombolysis using alteplase, administered
between 0 and 4.5 hours after the onset of stroke symptoms, was an effective treatment for acute
ischaemic stroke. The treatment window was extended to 4.5 hours from the previous cut-off of 3 hours
post symptom onset in 2012.2,4
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Although not submitted in time for the NICE review, the results of IST-35 have subsequently been
published. The trial found that for every 1000 patients who receive thrombolytic treatment within 3 hours
of stroke, approximately 100 more will survive alive and independent compared with 1000 patients not
given thrombolytic treatment. Similarly, a benefit was also found for patients treated within 6 hours of
stroke, but a smaller effect was observed in that approximately 50 more will be alive and independent
compared with those not treated with thrombolysis. The trial also confirmed a benefit of treatment among
patients aged > 80 years when treated within 3 hours of symptom onset. However, the benefit was not
as strong when treating patients aged > 80 years closer to the 6-hour mark.
In a recent update to the Cochrane review on thrombolysis for acute ischaemic stroke,6,34 the authors
concluded that thrombolytic treatment delivered < 3 hours after stroke symptom onset significantly
reduced death or dependency at 3–6 months, but that at progressively later times to treatment, the
benefit decreased, disappearing between 4.5 and 6 hours. It was also noted that the pooled trial data16
had demonstrated a significant reduction in death or dependency with treatment within 6 hours of
symptom onset, but there was significant heterogeneity observed between trials.
Licensing criteria currently restrict treatment to patients aged ≤ 80 years, but most clinicians now treat
patients aged > 80 years on the basis of recent trial evidence5 and recognition of the distinction between
chronological and physiological age. The ECASS-III35 trial supported extension of the time window for
treatment from 3 to 4.5 hours and the European licence time window was extended.3 However, according
to the Safe Implementation of Thrombolysis in Stroke-Monitoring (SITS-MOST) study, it is common for
patients outside the licensing criteria to be treated,36 suggesting that different clinicians are satisfied with
different levels of evidence and/or vary in their decision-making process regarding patient eligibility given
the same evidence. Yet little is known about the source or drivers of this variation.
In recent years, there has been considerable debate between proponents of thrombolysis and those who
question its efficacy. There have been arguments presented in prominent journals, such as the British
Medical Journal,21,25 as well as papers targeted towards an emergency medicine audience.24,26,37,38 These
articles describe the evidence base for thrombolysis as uncertain and call for a reappraisal of the evidence,
advocating the view that the risks of thrombolysis in acute stroke outweigh the potential benefits of
treatment. These debates have also been the focus of recent media attention39 and, therefore, clinicians
are likely to be aware of these ongoing issues.
As a result of these debates and public controversies surrounding other treatments, the Chief Medical
Officer for England has called for an independent review of the safety and efficacy of medical treatments,
and thrombolysis will be included in this Academy of Medical Sciences review.39 An independent
investigation of thrombolysis by the Medicines and Healthcare products Regulatory Agency has recently
been published, confirming the benefit of thrombolysis for patients with acute ischaemic stroke.39
The next section explores the factors that have been shown to influence clinical decision-making and
factors that have been specifically implicated as influential in decision-making about thrombolysis.
Influences on clinical decision-making
There are myriad factors that may influence the clinical decision to offer intravenous thrombolysis. These
factors may be considered in three broad categories: patient-related factors, clinician-related factors and
environmental/systemic factors. This section will explore each of these influences.
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Patient-related factors that can influence clinician decision-making
An international Delphi study conducted in 2007 sought to establish consensus on the relative
contraindications for offering intravenous thrombolysis in acute ischaemic stroke.20 Although agreement
was reached on 12 of the 18 patient factors, there was a failure to reach consensus on factors such as
stroke onset time to treatment, recent medical procedures, spontaneous improvement rate and blood
pressure treatment (Table 1).20 This study highlighted the variation between expert clinicians in their
attitudes towards factors that influence decision-making about thrombolysis and underlined the degree to
which ‘grey’ areas remain in the evidence base.
Studies have suggested that sex may have a population-level effect on thrombolysis administration, with
evidence of the underutilisation of intravenous thrombolysis in women,40 although this may reflect a
different age and presentation profile in women.41 This is despite a pooled analysis of randomised
controlled trials demonstrating that women are more likely than men to benefit from thrombolysis.42,43
Research to assess and clarify the impact of sex on thrombolysis utilisation and outcomes using individual
patient data collated from randomised trials is ongoing and should clarify this effect, if any.15
Uncertainty exists regarding a number of patient factors, where there are ‘grey’ areas in the guidelines
and/or research evidence. Patient factors, such as pre-stroke disability, stroke severity and comorbidities,
can operate as a major influence on clinicians’ consideration of the potential risks and benefits of
thrombolytic treatment. Research has explored whether or not pre-stroke disability was associated with
negative outcomes of thrombolysis.44 It was concluded that pre-stroke disability does not independently
increase the risk of sICH after thrombolysis. However, higher modified Rankin Scale (mRS) scores (high
scores indicating greater dependency on others for assistance with daily living) were associated with an
increased risk of death at 3 months post treatment. Despite this, the authors state that as one-third of
previously disabled patients can return to their pre-stroke dependency, these patients should not be
excluded from treatment with intravenous thrombolysis.
Uncertainty also exists regarding minor strokes and self-limiting transient ischaemic attacks. Relatively
minor symptoms may lead clinicians to believe that patients are not sufficiently impaired to warrant
treatment, based on the perceived risk of treatment. Furthermore, the licensing criteria state that clinicians
should exclude patients as eligible for treatment when there is a ‘minor neurological deficit or symptoms
rapidly improving before start of infusion’45 and, thus, clinicians may withhold or delay thrombolysis where
TABLE 1 Summary of results of Delphi study to establish consensus on contraindication for thrombolytic treatment
Factors where consensus was reached Factors where consensus was not reached
Previous stroke Stroke onset to treatment time
Previous head trauma Recent surgery
Recent gastrointestinal haemorrhage Spontaneous improvement rate
Recent urinary tract haemorrhage Blood pressure reduction
Stroke severity Patient age
Systolic blood pressure Recent arterial puncture
Diastolic blood pressure
Platelet count
Maximum serum glucose level
Minimum serum glucose level
International normalised ratio
Activated partial thromboplastin time
BACKGROUND
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symptoms are mild or improving.46 Many clinical trials excluded patients with low NIHSS scores (usually
NIHSS score of ≤ 3–5), limiting the evidence base for such patients. However, a recent Austrian study
found that those with a mild deficit (NIHSS score of ≤ 5) had significantly improved outcome with
thrombolytic therapy, compared with matched cases who did not receive thrombolytic treatment.47 A
pooled analysis of individual patient data from stroke trials demonstrated better outcomes in patients with
mild ischaemic stroke (NIHSS score of ≤ 4) treated with thrombolysis, although < 10% of enrolled patients
had mild stroke.15
Clinicians may also delay treatment or decision-making with thrombolysis if blood pressure is high
(> 185/110 mmHg). Active blood pressure lowering is associated with an increased proportion of patients
being treated with intravenous thrombolysis,48,49 compared with a conservative strategy, without a
difference in sICH rate.
Clinician-related factors that can influence clinical decision-making
There is strong evidence that clinician-related factors can have a significant influence on medical
decision-making.50 Shamy et al. recently conducted a study which addressed the decision of administering
intravenous thrombolysis for acute stroke.51 In their online survey of 70 neurologists in Ontario, Canada,
they found that respondents were less likely to administer thrombolysis to patients over the age of
80 years, to patients from nursing homes and to patients diagnosed with dementia.51 Post-hoc analyses
revealed that neurologists who consulted on more than 10 acute stroke cases per month were significantly
less likely to treat large strokes and those with more than 10 years of clinical experience were significantly
more likely to administer thrombolysis to patients with dementia.
Further clinician-centred influences on the consideration of thrombolysis have been postulated, and include
factors such as concern about adverse effects, especially sICH, and uncertainty about effectiveness.37,52
Recent academic debates regarding the efficacy of thrombolysis are also likely to impact on clinicians’
decision-making and might have influenced clinicians’ perception of the evidence base and confidence in
the efficacy of thrombolysis. Attitude towards thrombolysis has been independently associated with
willingness to administer thrombolysis,37 and clinicians’ interaction and involvement with their professional
community and information-seeking behaviour can also influence medical decision-making.53
In the wider literature on clinical decision-making, several factors, including clinicians’ age, sex, medical
specialty and level of experience, have been shown to influence decision-making. For instance, level of
experience54 and characteristics of clinicians (e.g. their medical specialty, age and ethnicity) can interactively
influence decision-making.55 A study examining variation in diagnostic decision-making in heart failure
(a similarly complex decision characterised by high levels of uncertainty) found that clinician characteristics,
such as grade or level of seniority, influence how evidence is weighted and used to inform a diagnostic
decision.56
Personality and individual values also differ among clinicians, potentially influencing decision-making.
Research indicates that personality characteristics are associated with working in certain medical
specialties57 and can predict the choice of person- or technique-oriented medical specialty.58 Individuals can
also differ in their approach to risk,59 and risk assessment is a routine component of clinicians’ everyday
practice. The perception of risk can be influenced in many ways, such as through interaction with the
patient and other clinicians and through the clinicians’ own attitudes towards risk. Personal attitude to risk
has been explored in previous decision-making research, and a US-based study found that emergency
medicine physicians’ scale scores correlated significantly with their rates of admission for patients with
acute chest pain, in that individuals in the high-risk-taking group were less likely to admit patients after
treatment than colleagues scoring as low risk takers.59
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Another relevant feature of clinical decision-making in practice is making decisions in uncertain
circumstances, for instance when a diagnosis is unclear or when details about the patient’s history may
be incomplete or unknown. A systematic review of the barriers to delivery of thrombolysis found that
physician uncertainty about administering thrombolysis was a key barrier.52 Gerrity et al. developed a scale
to assess physicians’ affective reaction to uncertainty.60,61 Research employing this measure found that it
has been associated with decision-making. For instance, primary care providers with higher levels of
anxiety about uncertainty were more likely to refer a chronic kidney disease patient to a nephrologist.62
Clinicians are also vulnerable to the cognitive biases that affect us all. These are cognitive ‘rules of thumb’
that are based on experience and serve to reduce cognitive load.54 While they are a mechanism by which
rapid clinical decisions can be made in typical circumstances, they can also result in error and decision-
making bias if adhered to rigidly in situations which are atypical. The availability bias is one which may
influence the decision to offer intravenous thrombolysis. Availability may be described as the tendency for
things to be judged as occurring more frequently, or as more likely to occur, if they can be readily brought
to mind: that is, they are available and easily accessible in memory. This can lead to distortion in estimates
of base rates (i.e. risk of sICH) and may lead clinicians to under- or overestimate the probability of a
negative outcome of treatment. Even clinicians who are cognisant of the potential bearing of cognitive
biases on clinical judgement and decision-making may still be susceptible.63
Clinicians’ may also vary in their willingness to control blood pressure before administering thrombolysis,
as this was not standardised during the trials which produced evidence about the efficacy of thrombolysis
for stroke. A recent study48 found that active blood pressure lowering was associated with an increased
proportion of patients treated with intravenous thrombolysis, compared with a conservative strategy,
without a difference in sICH rate. However, it is unclear if all clinicians would be comfortable with actively
trying to lower blood pressure before administering thrombolysis.
Taken together, this literature highlights the variation that can exist between clinicians, even when
consulting on identical cases, and thus underscores the importance of examining both patient factors and
clinician factors in a decision-making model.
Environmental/systemic factors that can influence clinical decision-making
Research suggests that the culture within a hospital or treatment centre can impact on decision-making
and practice style.64–66 A study conducted in the Netherlands found that several features of organisational
culture were positively associated with rates of thrombolysis administration, including the availability of
feedback on practice, a learning culture and clinical leadership.67 Structural factors such as access to CT
scanning might previously have had an influence on variation on intravenous thrombolysis rates in the UK;
however, with the widespread implementation of ‘24/7’ hyperacute stroke services and the extension of
telemedicine facilities,68 continuing variation is likely to reflect differences in clinical decision-making.
Summary and conclusions
It is clear that there are multifaceted influences on clinical decision-making more broadly and specifically
on thrombolysis decision-making. It remains unclear which specific patient- and/or clinician-related factors
influence the clinical decision to offer thrombolysis to patients, and especially their relative contributions to
variation in treatment rates. In order to better understand clinical decision-making about intravenous
thrombolysis, a study to explore factors influencing clinicians’ reasoning is warranted. Given the recorded
variation in thrombolysis treatment rates, the lack of expert consensus on several exclusion criteria for
treatment and the ongoing debates regarding the efficacy of thrombolysis, a robust method is required
that facilitates an understanding of the preferences of clinicians who are making these decisions in a
way that most closely reflects decision-making in practice. This study aimed to identify the factors that
contribute to variation in, and influence, clinicians’ decision-making about offering intravenous
thrombolysis to patients with acute ischaemic stroke.
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Chapter 3 Research methodology
Rationale for a discrete choice experiment
A DCE is a method used to explore the relative importance of different factors in a decision-making
process. Based on the principles of random utility theory and on Lancaster’s theory of demand,69,70 DCEs
operate on the tenet that multiple factors/attributes influence decision-making and that all choices involve
trade-offs. The DCE approach offers a means through which the nuances of decision-making, which are
not easily accessed through other more traditional research methods, can be understood.
As summarised in Table 2, other methods to explore variation in clinicians’ decision-making about
thrombolysis have weaknesses and are inappropriate to capture the nuances underlying complex
decision-making processes. For this reason, the Delphi method cannot adequately address the research
question, as it seeks to establish consensus among experts rather than explore the variation and
differences in decision-making. Furthermore, a previous Delphi study20 aiming to reach consensus on the
TABLE 2 Advantages and disadvantages of alternative approaches to understanding variation in thrombolysis
decision-making
Method Advantages Disadvantages
Delphi study Facilitates a group communication process to
address a complex problem with the aim of
achieving consensus
Focus is on achieving consensus rather than
understanding variation in decision-making
Delphi study has already been undertaken which
demonstrated the need to better understand
decision-making20
Ethnography Observation of real-time decision-making processes
in actual clinical practice
Ethical and practical constraints around observing
clinical decision-making in an emergency context
Focus is usually on the observed behaviour rather
than exploring the underpinning thought processes
that shape the decision made56
Difficult to observe infrequent events
Audit More straightforward to access and conduct Focus on the decision outcome rather than the
factors that shape decision-making, many of which
will not be recorded in medical records
Provides information on decisions made but does
not capture trade-offs in decision-making
Audit data have limitations such as the extent and
completeness of the data set
Analysis of audit data shows variation, but does not
explain it with regard to decision-making71,72
DCE Unpacks the factors shaping decision-making and
enables exploration of the trade-offs made and
how these vary across a population of
decision-makers
There may be challenges in explaining the method
and the decision task to participants
DCEs have been criticised on the grounds that
participants might behave differently under test
conditions from how they would behave in reality.
However, DCE allows design of the choice set to
mimic as closely as possible the decision of interest
using vignettes designed with emphasis on clinical
face/content validity to enhance external validity27
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contraindications for thrombolytic treatment failed to achieve agreement on several indicators, further
highlighting the variation that exists between clinicians in their decision-making when there is a lack
of clinically applicable evidence. Similarly, although an ethnographic approach could provide rich
observational qualitative data, such data give insights into the observable processes of decision-making
rather than the implicit thought processes that shape those decisions. In addition, there are significant
ethical and practical issues associated with undertaking observations in an emergency context. For
instance, there would be difficulties in accessing an emotionally charged and sensitive situation and,
coupled with the relative infrequency of this decision-making scenario, the researcher would need to be
present for very long periods in order to access small numbers of decision-making events. Finally, insights
from audit data are dependent on the extent, level of detail and completeness of the data set and may
not be fit for purpose, and they cannot address the nuances of decision-making. For instance, the
SITS-MOST database36 is limited to thrombolysed cases only and SSNAP does not collect information
on all patient and clinician factors that could influence clinical decision-making.
High levels of external validity have been demonstrated in DCEs in a number of areas in which DCEs have
been applied, including in health, environment and transport settings.73,74 For example, in a study of
physicians’ prescribing decisions, stated preference responses to hypothetical scenarios were shown to align
with revealed preference (i.e. preferences under simulated conditions aligned with actual behaviour).74
In particular, data collected in DCEs are used to model choice (in this case of whether or not to offer
thrombolysis) as a function of the attributes of the alternatives between which respondents are asked to
choose (in our case the characteristics within the patient vignettes) and the characteristics of the
decision-makers (the clinicians’ characteristics). This makes DCEs ideally suited to investigate which
attributes described in the vignettes are important to clinicians when deciding to offer thrombolysis.
Following testing, the preferred model can be chosen based on goodness-of-fit indicators such as Akaike
and Bayesian information criteria.27 Predicted probability analysis can investigate the probability of offering
thrombolysis using clinically relevant values on the attribute levels. DCEs have been increasingly adopted
to examine decision-making in areas of health care (e.g. to explore patient preferences for early stroke
rehabilitation management8 and patient preferences for atrial fibrillation medication75), but none has
examined the factors that influence clinicians’ decisions to offer thrombolysis.
Issues to consider in discrete choice experiment design
and development
Traditionally, the design of a DCE is informed by literature review, expert opinion, theoretical arguments
and/or qualitative work. However, there is no standard development process for a DCE, owing to the
variable nature of the type of factors that may be included and the optimal presentation mode of choice
sets or decision alternatives. As a result, the processes involved in the design of DCEs are often poorly
described, with little or no detail reported regarding the procedures for selection of factors/levels in the
final design.76 In particular, there is a dearth of information on procedures undertaken to refine the
number of factors and their associated levels and, when reported, this information has been characterised
as ‘excessively brief’.76
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) has published two reports
on recommended research practice for DCEs.77,78 These publications include advice on evidence-based factors
and level selection, as well as a checklist for researchers to ensure best practice in the development,
administration, analysis and reporting of DCEs. However, these guidelines do not offer a clear approach to
DCE factor/level selection. Therefore, this research builds on these guidelines by offering a transparent
approach to DCE development, which may be employed in other settings.
In the following section, we describe the multistage process undertaken to develop and conduct an online
DCE to explore factors influencing clinical decision-making about intravenous thrombolysis in the treatment of
acute ischaemic stroke. This process was guided by ISPOR recommendations for research practice, as well as
recent published advice on the development and design process,7,76–78 to ensure optimal design of the DCE.
RESEARCH METHODOLOGY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
10
Overview of design process adopted in current study
The development process consisted of five iterative stages (Figure 1) in the development of an online DCE.
We designed hypothetical patient vignettes to mimic as closely as possible the decision of interest. In
contrast to the typical tabular approach to DCE presentation, vignette-style presentation was considered
optimal for this study, as clinicians tend to be familiar (and probably more comfortable) with vignettes
because these are regularly used in training and CPD. The decision of interest was a binary response to
the hypothetical vignette (decision to offer thrombolysis or not), as this reflects routine clinical practice
whereby clinicians are faced with one patient at a time and must decide whether or not to offer
thrombolysis to that patient.
Stage 1: exploratory work
In the initial stages, we considered all factors that might be important for a clinician in decision-making, as
omitting potentially important factors in the DCE may bias findings.7 We drew on qualitative data collected
in a previous research programme examining decision-making in acute stroke14 and on work to inform the
development and testing of a computerised decision support tool for thrombolysis in acute stroke care.79
This included qualitative interview data on the views and experiences of stroke clinicians about thrombolysis
decision-making, ethnographic data collected through non-participant observation of thrombolysis
decision-making discussions and data from the usability and feasibility testing of the decision support tool.
Relevant literature was also reviewed to help to identify further factors that have been documented to affect
decision-making about thrombolysis and factors influencing clinical decision-making more broadly.20,51,52,80–82
In addition, nine telephone-based semistructured interviews were conducted with stroke clinicians and
leading experts in stroke research. The sampling strategy was purposive in order to capture the views of
clinicians who had not contributed to the development and testing of a stroke thrombolysis decision
support tool (Computerised Decision Aid for Stroke Thrombolysis; COMPASS), and targeted clinicians from
hospitals in both the upper and lower quartiles of thrombolysis rates, based on figures from national
audit reports.19 These interviews aimed to identify any additional patient-related factors or levels that
represented the borderline and/or difficult cases, in particular the nature of trade-offs made between
influential factors and levels when making decisions about whether or not to offer thrombolysis.
Interviews were audio-recorded and transcribed verbatim and anonymised transcripts were then imported
into QSR International’s NVivo 9 (Warrington, UK) to facilitate the coding and analysis of data. The
resulting data set was coded thematically and analysed using a framework approach.83 This qualitative
analysis of interview data and review of secondary data sources from the Development and Assessment of
Services for Hyperacute stroke (DASH) Programme Grant for Applied Research,14 alongside the literature
review, facilitated the generation of a comprehensive list of 22 potentially influential patient-related factors
on clinical decision-making regarding thrombolysis (Box 1).
Stage 2: expert panel discussions – inclusion and exclusion criteria
Exploratory work commonly identifies too many factors/levels to include in DCEs and, owing to sample size
constraints and the potential for respondent cognitive burden, it is often not practical or feasible to include
all possible combinations that may influence decision-making. By including all potentially influential factors
and levels of interest, the statistical power of a DCE to detect effects would be reduced, owing to the
large number of possible combinations of levels and the inability of a small sample size to adequately
assess all these various combinations. Methods are needed to select the most important factors and levels
to include in a testable DCE. Although there are publications that provide generic advice,76,84 there is little
agreement on the best approach to achieve this. A well-designed DCE has been described as ‘one that has
sufficiently rich set of attributes and choice contexts, together with enough variation in the factor levels
necessary to produce meaningful behavioural responses’.27 Abiiro et al.85 advise employing quantitative
methods, such as ranking exercises, to support the process of selecting factors for inclusion to a
manageable number.
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In the first instance, the expert multidisciplinary panel in the current study (consisting of three stroke
physicians who undertake clinical research, a trainee stroke physician, two patient representatives, two
health psychologists, two health economists and an expert in shared decision-making) screened the list of
factors in terms of whether they would be feasible or meaningful to include in a DCE, to be further
scrutinised using a structured prioritisation exercise (SPE). Following discussions, a set of inclusion and
exclusion criteria were agreed with reference to the study objectives (i.e. the study focus on decision-making
in acute ischaemic stroke and not on diagnosis of acute stroke).
Removal of factors that could be considered as related to uncertainty
regarding the diagnosis of acute ischaemic stroke
This was considered prudent based on the rationale that incorporating diagnostic uncertainty has
methodological implications for the design of the patient vignettes and interpretation of results from the
DCE. Given that a diagnosis of acute ischaemic stroke represents a gradient of certainty (and includes
consideration of differential diagnoses such as transient ischaemic attack and stroke mimics), this does not
lend itself well to the DCE framework. Furthermore, diagnostic uncertainty is outside the aims stated in the
study protocol86 to explore factors influencing decisions to offer thrombolysis as opposed to what factors
influence diagnosis.
BOX 1 Patient-related factors that could influence decision-making about thrombolysis
1. SBP.
2. DBP.
3. Blood glucose level (BM).
4. Patient frailty.
5. Stroke severity (NIHSS score).
6. History of hypertension.
7. History of stroke.
8. Anticoagulation status/INR level.
9. Aspirin monotherapy.
10. A patient’s level of social support.
11. Major surgery in past 3 months.
12. Presence of diabetes at time of presentation.
13. Patient age.
14. Patient ethnicity.
15. Patient sex.
16. Socioeconomic status of patient.
17. Stroke onset time to treatment.
18. Recent infarction on CT/MRI scan.
19. Pre-stroke cognitive functioning/capacity/comprehension of risk information.
20. Pre-stroke dependency status.
21. Patient/relative values, knowledge and views on thrombolysis.
22. Comorbidities.
DBP, diastolic blood pressure; INR, international normalised ratio; MRI, magnetic resonance imaging;
SBP, systolic blood pressure.
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Removal of redundant/uninformative questions from the structured
prioritisation exercise
Questions were excluded if the panel agreed that the area of uncertainty on any factor had been clearly
identified by the literature and/or qualitative data. For instance, a question regarding a patient’s pre-stroke
status using the mRS was removed, as the panel were confident that most clinical variation in decision-making
exists between mRS2 and mRS3.
Furthermore, factors were omitted that have been shown to have a population-level effect in research
studies but were not considered by the expert panel (or were not identified in exploratory interviews) to be
important for decision-making about thrombolysis at the individual patient level (e.g. patient’s current use
of aspirin).
Stage 3: phase 1 – design of online structured prioritisation exercise
An online SPE was designed to ascertain the perceived relative importance of various patient-related factors
for clinical decision-making about thrombolysis, as well as to help to identify the ‘grey’ areas and areas of
uncertainty on specific factors. Questions were phrased to identify where uncertainty and ‘cut-offs’ existed
on individual factors regarding the suitability of the patient for intravenous thrombolysis: for example,
Assuming all other indications point to thrombolysis, at what blood pressure levels [systolic and
diastolic] would you no longer think it appropriate to offer intravenous thrombolysis?
Free-text boxes were provided after each question to capture any comments respondents had to provide
more information about their response. The SPE was hosted on Qualtrics (www.qualtrics.com) and
30 stroke clinicians in the north-east of England were invited to participate. The rationale for limiting the
sample to clinicians in this region was to avoid priming too many in the population who would be invited
to participate in the main study. The SPE is included in this report as Appendix 2.
Stage 3: phase 2 – using the structured prioritisation exercise to inform
selection of factors/levels
Based on the results from the exploratory work (Table 3), the SPE and expert panel discussions, the expert
panel (n = 6) ranked each factor in order of priority for inclusion in the DCE (based on those which were
perceived to have the greatest influence on thrombolysis decision-making), indicated how they would
operationalise them and provided suggestions on possible levels for each patient-related factor (Table 4
provides the results). Results were then aggregated and fed back to the panel to inform the discussion on
the selection of the final list of factors and levels for inclusion.
There was a need to compromise on the perceived importance of factors to ensure that concerns
regarding sample size/design feasibility, ecological validity (i.e. ensuring that information presented is as
consistent as possible with information that would be available in a real-life situation) and the potential
impact of unconscious factors (e.g. patient ethnicity) were considered in the final factor selection process.
Among the issues considered during these panel discussions were:
l Ensuring clinical face validity. It was vital that patient information presented in vignettes was realistic
and that factors and levels could plausibly occur together. Certain factor levels could not reasonably
appear together meaningfully; therefore, some initial constraints were imposed on the design. For
instance, a mRS score of 0 or 1 (indicating that the patient is able to carry out all usual duties and
activities) was considered implausible for a patient described as having severe dementia. Vignette-style
presentation was considered optimal, as clinicians tend to be familiar (and probably more comfortable)
with vignettes because these are regularly used in training and CPD. Consequently, participating
clinicians were unlikely to treat the exercise as a test and, thus, to behave differently from how they
would in the real world. Similarly, vignettes (as opposed to a traditional tabular list of attributes and
levels that are commonly used in DCEs) more closely reflect the way in which clinicians receive
information about their patients, thereby increasing the realism of the decision task.
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TABLE 3 Results of online survey (SPE)
Factor
Potential levels
(‘grey’ areas) Evidence
Rationale for
inclusion/exclusion
(A) SBP 180–184mmHg
185–189mmHg
190–194mmHg
Identified as upper cut-off points in
the SPE
Qualitative work indicated that was
SBP was a highly influential factor
Dirks et al.:20 Delphi study
agreement of > 185/110 mmHg as
cut-off
Kent et al.:42 higher SBP= less
benefit from thrombolysis
NICE guidelines (2008)87 stated that
SBP reduction to ≤ 185/110 mmHg
should be considered in people
who are candidates for
thrombolysis
Most important factors identified
in SPE and a primary issue
identified in qualitative
exploratory work
(B) SBP control SBP at decision time
after attempt to
reduce
SBP at patient
presentation
(no attempt to
reduce SBP made)
The level at which a clinician would
consider lowering SBP as a separate
issue to at what level they are
prepared to treat
11 out of 12 clinicians who
responded to the SPE reported they
would attempt to reduce SBP
if necessary
(C) DBP 100–104mmHg
105–109mmHg
110–114mmHg
115–119mmHg
Delphi study20 agreement of
110 mmHg as cut-off
Ranked 3 out of 19 in SPE,
indications of variation in
acceptable upper level
(D) NIHSS score/
stroke severity
Lower end: 0, 1, 2, 3
Upper end: > 25
Qualitative work identified NIHSS
score of ≤ 3 as creating uncertainty
around offer of thrombolysis;
4–25 = typical treatment zone;
> 25= higher risk and reported as
cut-off for some
SPE: clinicians commented that
aphasia is more disabling than
NIHSS suggests and this would be
an important consideration
(qualitative work indicated that
NIHSS is not always considered to
be reliable indicator of severity)
Ranking in SPE table: 10 out of 19
Evidence for variance in
acceptable lower and upper limit
(E) Pre-stroke
cognitive status/
capacity of patient
No cognitive
impairment
Moderate cognitive
impairment
Severe cognitive
impairment
Identified as an important factor by
Shamy et al.51
Emerged as influential in qualitative
findings (to varying degrees and
depending on other factors
including NIHSS, dependence on
others for activities of daily living,
impact on quality of life)
Ranked 8 out of 19 in SPE
Little previous research on this
continued
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TABLE 3 Results of online survey (SPE) (continued )
Factor
Potential levels
(‘grey’ areas) Evidence
Rationale for
inclusion/exclusion
SPE: severe cognitive impairment
would influence decision-making
of 64% of respondents; 27%
reported no influence. Suggested
that decision is influenced by the
patient’s functional status
(F) Patient’s pre-
stroke dependency
status (ADL)
Living independently/
24-hour support with
ADL (nursing home)
Pre-stroke mRS score
of > 2
Shamy et al.:51 clinicians less likely
to offer thrombolysis to patients
who were residents of nursing
homes
Ranked 4 out of 19 in SPE
(G) Frailty Based on reliance on
others/presence of
comorbidities or use
of composite factor/
absence or degrees
of frailty
Major issue in qualitative work:
clinicians concerned/nervous about
treating very frail, elderly patients;
concern regarding falls and
potential underlying injuries
SPE: 82% reported taking frailty
into account when making
thrombolysis decisions so this is
clearly an important influential
factor on decision-making
Ranked 5 out of 19 in SPE table
Difficulty operationalising
gradient of frailty; could include
as dichotomous variable:
frail/not frail
(H) Patient age General agreement
on no upper limit
Lower age limit
14–18 years
Evidence indicates patients aged
> 80 years receive similar benefit as
those aged ≤ 80 years, particularly
when treated earlier6
Not considered important in SPE
Some more likely to adhere to
licence than others
(I) Anticoagulation
status/INR level
< 1.6
< 1.7
< 1.8
Qualitative work found variation in
acceptable levels (1.5–1.9)
SPE indicated grey area was
between 1.6 and 1.8
Recent evidence suggests
thrombolysis when INR is ≤ 1.7
does not increase mortality risk/risk
of bleeding;88 observational studies
of bleeding risk among warfarin-
treated patients receiving
thrombolysis have been small
and inconsistent89
Ranked 2 out of 19 in SPE
May be possible to include
within subset of patients
(J) Patient/relative
preferences
regarding
thrombolysis
Patient lacking
capacity and family
not present (best
interests)
Relatives in favour of
thrombolysis
Relatives
against thrombolysis
Qualitative work: difficulty in
communication risk/benefit
information; concern patients/
family did not fully understand/
remember information under such
stress. Some clinicians expressed
discomfort making decision on
behalf of patients when family
members were not present
Preferences of family/patients
regarding thrombolysis cited as a
barrier to optimal decision-making82
Review papers52,80 found evidence
that delays in obtaining informed
consent were considered to
be a factor that delayed
treatment delivery
Ranked 6 out of 19 in SPE
Challenging to operationalise
in DCE
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TABLE 3 Results of online survey (SPE) (continued )
Factor
Potential levels
(‘grey’ areas) Evidence
Rationale for
inclusion/exclusion
(K) Major surgery
in past 3 months
Percutaneous
coronary intervention
(no time limit,
< 1 week)
Laparotomy for a
perforated duodenal
ulcer (SPE ‘grey’
areas: 2, 3, 4 weeks)
Failure to reach agreement in
Delphi exercise regarding time since
previous surgery20
Ranked 7 out of 19 in SPE
Variation in acceptable times
since major surgery
(L) Blood
glucose level
22–23.9 mmol/l
24–25.9 mmol/l
26–27.9 mmol/l
SPE: variability among respondents;
25% said no upper limit
Delphi study agreement of glucose
levels 2.7–22mmol/l20
Indications of variability
between clinicians
(M) Willingness to
treat to lower
blood glucose level
Attempt has been
made or has not yet
been made to lower
blood glucose
SPE: 66% would not seek to
control blood glucose level before
making thrombolysis decision
(N) Presence
of diabetes
History of type 2
diabetes
No history of type
2 diabetes
Patients with diabetes had better
outcomes when treated with
thrombolysis than controls
with diabetes90
Ranked 14 out of 19 in SPE
(O) Comorbidities Qualitative work, e.g. undergoing
cancer treatment, aneurysms
(P) Previous stroke Moderate stroke
NIHSS score of 7–12
(within previous
3 months)
Severe stroke NIHSS
score of ≥ 13 (within
previous 3 months)
Patients with previous stroke had
better outcomes when treated with
thrombolysis than controls with
previous stroke90
From SPE: previous severe stroke
ranked as more important
(ranking: 10) than previous mild
stroke (13)
(Q) Time since
onset of symptoms
3∼4.5 hours
> 4.5 and
< 5–6 hours?
Qualitative work: 4.5 hours was
upper cut-off for most, but some
clinicians were more willing to
accept uncertainty around
onset time
(R) Level of
social support
No/or minimal social
support
High level of
social support
All SPE respondents indicated that
a patient’s level of social support
would not impact on their decision-
making about thrombolysis
ADL, activities of daily living; DBP, diastolic blood pressure; INR, international normalised ratio; SBP, systolic blood pressure.
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TABLE 4 Results of expert panel ranking exercise
Factor Mean rank (SD)a Median Suggested levels
SBP 1.67 (1.2) 1 140mmHg
175mmHg
180mmHg
185mmHg
200mmHg
Pre-stroke
dependency status
4 (2.6) 4 mRS1
mRS2
mRS3
mRS4
Pre-stroke cognitive
status
5.33 (2.6) 5.5 No impairment
Mild impairment
Moderate impairment
Severe impairment
NIHSS score/stroke
severity
6.5 (2.9) 7 NIHSS 2
NIHSS 3
NIHSS 5
NIHSS 23
NIHSS 25/26/27
SBP (after reducing) 6.6 (4.7) 5 185mmHg
190mmHg
200mmHg
INR/anticoagulation 6.7 (2.7) 5.5 < 1.6
< 1.7
< 1.8
2
DBP 6.8 (5.2) 6 100mmHg
110mmHg
115mmHg
120mmHg
Frailty 6.8 (3.9) 7 Composite measure using comorbidities, description of needs
(i.e. walking stick), ‘patient you [do not] perceive as frail’
Time since symptom
onset
7.8 (6.1) 7 < 1 hour
< 3 hours
4 hours
4 hours 15/20 minutes
Recent major surgery 8.3 (3.6) 7.5 Percutaneous coronary intervention
Hip replacement
Laparotomy
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l Ensuring sufficient information was present in vignettes. It was crucial to ensure that clinicians
had sufficient information available to reach a decision about the offer of thrombolysis. It was decided
that information on certain factors must be provided (as either variable or fixed factors) in the vignettes
in order for clinicians to reach a decision and for the decision-making process to mimic real-life
decisions as closely as possible. For instance, stroke severity score and the results of the CT scan were
considered vital information. Factor order/placement in the vignette was decided based on the
information that would be available to the clinician immediately and the typical order in which
additional information may be obtained. The order of presentation of factors was also informed by
work to develop the COMPASS decision support tool.79
At this point, we also considered the relative frequency of various presentations of acute stroke. It was
decided that relatively uncommon complications or patient characteristics (e.g. patient on warfarin or
had recent surgery) would be excluded to ensure that vignettes included those factors that were more
common to most patients (e.g. NIHSS score indicating stroke severity, patient age and patient sex).
Data from Safe Implementation of Thrombolysis in Stroke (SITS) helped to inform this discussion.91
TABLE 4 Results of expert panel ranking exercise (continued )
Factor Mean rank (SD)a Median Suggested levels
Previous stroke 9.2 (4.3) 10.5 Combine with stroke severity?
2 weeks ago
4 weeks ago
3 months ago
Comorbidities 9.8 (2.6) 10 Disability related
Chronic disease
Illness presenting bleeding risk
Blood glucose
level (BM)
10.8 (3.1) 11 16/19 mmol/l
22 mmol/l
25 mmol/l
27 mmol/l
Patient/relative
preferences
11.4 (2.6) 12 No family present
Family present and eager for patient to be treated
Family present and worried about bleeding risk
Willingness to treat
blood glucose
11.6 (3.7) 11 Option to treat before thrombolysis decision
Option to present already treated level
Patient age 12.7 (5.7) 14.5 62/68/75 years
80/85 years
95 years
Social support 15 (3.1) 16 Indicator of dependency?
Use as part of frailty composite measure?
Presence of diabetes 15.4 (2.4) 16 No history of diabetes
Patient has diabetes
DBP, diastolic blood pressure; INR, international normalised ratio; SBP, systolic blood pressure; SD, standard deviation.
a Lower mean rank indicates higher perceived importance.
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l Anticipated sample size and resulting design considerations. Although more levels can define the
true relationship between factors and their influence on decision-making, there is an inherent trade-off
between the number of factors and levels that can be included and the complexity of the design of the
DCE.27 Furthermore, there are important considerations regarding the maximum numbers of factors
and levels a participant can process at one time, as well as issues regarding sample size. Owing to the
limited size of the population of interest in the current study, restricting the number of variable factors
and levels per factor was necessary to control the number of potential combinations in order to ensure
that the DCE would have sufficient statistical power to detect important effects. The complexities and
problems of performing sample size calculations for DCEs have been highlighted.7 Optimal sample size
requirements for the limited dependent variable models of the nature estimated in DCEs depend on
knowledge of the true choice probabilities, which were not known prior to undertaking the research.73
However, previous DCE studies have shown that robust choice models can be estimated from sample
sizes of between 50 and 100 respondents.92,93 Based on previous studies and estimates of the total
number of clinicians treating acute stroke patients in the UK, a sample size of 150–200 was anticipated
as achievable in the current study. This estimate represents approximately 35–47% of the 422 clinicians
registered as ‘full members’ of the British Association of Stroke Physicians (BASP), although the
proportion involved in thrombolysis decision-making was unknown.94 Moreover, owing to the potential
for cognitive burden, we judged that 12–16 hypothetical patient vignettes would be the upper limit of
the number of decision vignettes that should be administered to each participant (and this would be
tested in the piloting of the DCE in stage 4).
Factors that were deemed important to provide basic clinical information (but not included as variables
in the DCE) were included as fixed factors in the design, meaning that they were described to
respondents and held fixed in the choice context. The use of fixed factors helped to remove subjectivity
around interpretation of additional issues, providing a common interpretation of such factors across
respondents while retaining face validity. In the current study, blood glucose level was included as a
fixed factor in each vignette, at a level of 6 mmol/l. An identical text description of a patient’s CT scan
result was included in all vignettes to remove subjectivity around imaging interpretation and to
minimise any uncertainty about diagnoses of acute ischaemic stroke.
Definitions were included to standardise the interpretation of factors and levels. For instance, the
standard definitions for mRS scores95 used to assess pre-stroke dependency were presented in each
vignette. Definitions were also provided to describe pre-stroke cognitive functioning and were
operationalised based on the Global Deterioration Scale for the assessment of primary degenerative
dementia.96 The calculation for each level of stroke severity was described using the NIHSS97 to ensure
consistent interpretation. These definitions are available in Table 3.
l Consideration of explicit versus implicit influences on decision-making. The expert panel
acknowledged the need to also consider implicit factors as having an impact on decision-making
about thrombolysis. There is strong evidence that implicit factors can be influential in medical
decision-making.81 Therefore, the panel also considered factors that did not emerge from the
exploratory work and SPE. For instance, there is a suggestion that sex may have a population-level
effect on thrombolysis administration, with evidence of underutilisation of intravenous thrombolysis in
women,40 although this may reflect a different age and presentation profile in women.41 This
suggestion comes despite a pooled analysis of randomised controlled trials demonstrating that women
are more likely than men to benefit from thrombolysis.42,43 The panel did not consider sex to be a
conscious consideration at the individual, bedside level. Some factors may have an implicit effect on
decision-making, such as ethnicity and social class. Panel discussions were focused on striking a balance
between the inclusion of both implicit and explicit factors which may influence thrombolysis
decision-making.
Consensus was reached during expert panel discussions on the factors and levels that were included in a
pilot DCE.
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Stage 4: pilot testing
A specialised software program, NGene (v1.1.1, Choice Metrics, Sydney, NSW, Australia; www.choice-metrics.
com/), was used to generate a fractional factorial (d-efficient) design. This facilitated the generation of a design
that was as balanced as possible, given the imposed constraints. A fractional factorial design was employed
owing to the relatively large number of variable factors (nine) included in the final DCE, with number of levels
varying from two to six on different factors. This allowed for the testing of a subset of possible combinations.
The use of a blocked design allowed the number of vignettes presented to any one participant to be reduced
to a number considered manageable in pilot testing to avoid overburdening participants. In each block,
13 hypothetical patient vignettes were presented to each participant.
The pilot testing of the initial DCE employed a ‘think-aloud’ approach that was guided by best practice
guidelines.98 This method asks participants to verbalise what they are thinking when responding to the
survey. The aim of this pilot stage was to facilitate further testing of the credibility of the vignettes among
the population of interest, examine participants’ understanding and interpretation of the task and
questions, check the usability of the survey on different systems and browsers, and gauge how long the
survey might take to complete.
Sixteen clinicians were invited to take part in pilot testing. Six agreed to take part and fully completed
the pilot. Based on the results of pilot testing, some amendments were made. For instance, when two
clinicians read that symptom onset began 4 hours and 15 minutes ago, they factored time to prepare the
thrombolysis bolus into their decision-making (as the thrombolysis time window for treatment is up to
4.5 hours post symptom onset). Therefore, thrombolysis bolus preparation time was included as an
additional fixed factor, stating that the treatment dose could be prepared within 5 minutes to address this.
The testing revealed that vignettes were credible, although a number of implausible combinations were
suggested and added as constraints (i.e. excluded from the design). These included low NIHSS scores with
aphasia combined with moderate/severe dementia. Three participants also commented that spacing should
be larger within tables to improve readability. This was amended prior to the final testing of the survey by
the expert panel. The pilot testing protocol is available in Appendix 3.
Stage 5: final expert panel discussions, key considerations and finalised
discrete choice experiment design
Key considerations of the development of this online DCE were the size of the population of interest, the
number of combinations of factor levels, respondent burden and likely response rate. It was crucial to
consider these issues alongside the perceived importance of various factors and levels. Table 5 displays the
fixed factors and levels included in the final survey and the rationale for their inclusion. Table 6 outlines
the final variable factors and levels included in the final DCE and Table 7 provides the definitions used on
various factors and levels. Based on our five-stage design process, we were confident that we had
provided sufficient information to allow clinicians to reach a decision by using fixed and variable factors.
The full survey is available in Appendix 4, and includes all demographic questions and scales used to collect
information on clinician characteristics. A sample vignette is included in Figure 2. Optional free-text
comment boxes were included after each vignette to allow participants to explain their decision-making
and include comments as they felt necessary. These were included to assist with data interpretation.
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TABLE 5 Fixed factors used in DCE and rationale for inclusion
Factor Rationale for inclusion Fixed level Rationale for level
Blood glucose level Variable levels may result in
diagnostic uncertainty
6 mmol/l Average blood glucose level based
on SITS data of treated patients
CT scan text
description
To avoid skill/subjectivity
around interpretation
of scans
CT scan was conducted
and is consistent with
ischaemic stroke; it shows
no haemorrhage or new
ischaemic changes
Decided not to include image
owing to potential variability in
CT image interpretation skill and
subjectivity; difficulty finding scans
to match multitude of various
patient characteristics. Text
description deemed most
appropriate to remove
diagnostic uncertainty
To ensure confirmation
of diagnosis of acute
ischaemic stroke
Anticoagulation
status
Although it was deemed
an influential factor, only a
minority of stroke patients
take an anticoagulant
and therefore it was not
included as variable factor
Patient is not on
anticoagulation therapy
To avoid any issues surrounding INR
levels that could complicate the
decision to offer thrombolysis
Bleeding risk/
recent surgery
Relevant for only a minority
of patients. Challenging to
operationalise variable
and comparable levels
in vignettes
No recent history of
major bleeding
Diabetes Not ranked as important
in vignettes
No history of diabetes
Included as fixed factor for
clinical validity
Patient consent/
family assent
Assume either patient
consent or family assent is
available for treatment
Other/comorbidities There are no other factors
which would deter
treatment
Owing to difficulty defining fully
and generating comparable and
feasible levels of comorbidities.
Potential overlap with pre-stroke
cognitive and pre-stroke
dependency status
Fixed factors included post-pilot testing (stage 4)
Handedness of
patient
All patients are
right-handed
To clarify and ensure that the
deficits will be interpreted
consistently across all level of stroke
severity (NIHSS)
Licensed dose
bolus preparation
time
Can be prepared for
administration within
5 minutes
Pilot testing revealed that
participants would factor in variable
times in their decision-making and
so stating this will help to control
this potential error
INR, international normalised ratio.
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TABLE 6 Final list of variable factors and levels in the DCE
Factor Levels Rationale
1. SBP 140mmHga
185 mmHg
200mmHg
Highest ranked factor in stage 3 phases 1 and 2
Levels include those across range from ‘safe to offer
thrombolysis’ to ‘grey area’ to ‘outside the licensing guidelines’
2. Sex Malea
Female
To increase clinical face validity
To examine if sex has an unconscious influence on
decision-making
3. Age (years) 68a
85
95
Included for purposes of ecological and face validity
Evidence from exploratory work that some clinicians may take
patient age into account and adhere to current
licensing guidelines
4. Frailty You do not perceive
as fraila
You perceive as frail
Very challenging to adequately define frailty owing to
subjectivity in how clinicians view/consider it
Aim was to trigger perception of frailty in patient and therefore
the current phrasing was considered optimal to meet aim
5. Time since
symptom onset
50 minutesa
2 hours 30 minutes
4 hours 15 minutes
Potential greater benefit of very early treatment time
(50 minutes) included to compare with mid-point in time
window and rapidly approaching end of window (4 hours
15 minutes)
6. Pre-stroke
dependency
(mRS score)
mRS1
mRS3
mRS4a
Qualitative work suggested that mRS3 was the ‘grey’ area
in dependency
7. Pre-stroke
cognitive functioning
No history of memory
problemsa
Moderate dementia
Severe dementia
Exploratory work suggested that dementia/cognitive
functioning could influence decision to offer thrombolysis
8. Ethnicity Whitea
Afro-Caribbean
Asian
Included as a factor that may have an implicit effect on
decision-making
Included as this is information that would be obvious in a
typical decision
9. NIHSS score
(stroke severity)
NIHSS 2 (without aphasia)a
NIHSS 2 (with aphasia)
NIHSS 5 (without aphasia)
NIHSS 5 (with aphasia)
NIHSS 14
NIHSS 23
Presence or absence of aphasia deemed very important in
previous stage and therefore was included at lower NIHSS
scores (mild strokes) to assess whether it would influence
decision-making
NIHSS 14 included as it is SITS mean score (for treated patients)
NIHSS 23 considered a severe stroke
SBP, systolic blood pressure.
a Reference category.
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TABLE 7 Operational definitions for variable factor levels in the DCE
Factor Level Definition
NIHSS score
(stroke severity)
NIHSS 2
(with aphasia)
Mild-moderate aphasia (+1), LOC question (+1)
NIHSS 2
(without aphasia)
Right arm (drift +1), right leg (drift +1)
NIHSS 5
(with aphasia)
Right leg (some effort against gravity +2), drift in right arm (+1), mild
to moderate aphasia (+1), LOC question (+1)
NIHSS 5
(without aphasia)
Right leg (some effort against gravity +2), right arm (no effort against
gravity +3)
NIHSS 14 Face (partial paralysis +2), right arm (no movement +4), right leg (no
movement +4), dysarthria (severe +2), sensory loss (severe to total +2)
NIHSS 23 LOC questions (+2), LOC commands (+1), best gaze (+1), facial palsy
(+2), visual fields (complete hemianopia +2), no effort against gravity in
right arm (+3), no movement in right leg (+4), sensory loss (severe to
total +2), aphasia (severe +2), dysarthria (severe +2), extinction/
inattention (+2)
Pre-stroke cognitive
functioning
Moderate dementia Able to hold limited conversation but often requires prompting for daily
routine. Forgetful of recent events and people’s names
Severe dementia Cannot be left unsupervised. Wanders. No meaningful conversation.
Unaware of time and place
Pre-stroke dependency
status (using mRS)
mRS1 No significant disability. Able to carry out all usual duties and activities
mRS3 Moderate disability. Requires some help, but able to walk without
assistance
mRS4 Moderately severe disability. Unable to walk without assistance and
unable to attend to own bodily needs without assistance
LOC, level of consciousness.
An 85-year-old white man has been admitted to hospital with acute ischaemic sroke.
Symptom onset began 4 hours 15 minutes ago. The patient, whom you perceive as frail,
had a pre-stroke dependency mRS of 4. Further investigation revealed the patient is not
on anticoagulation therapy and has a blood glucose level of 6 mmol/l. The patient has
moderate dementia, and at the time of the treatment decision the patient’s systolic 
blood pressure was 140 mmHg. The patient has no recent history of significant bleeding 
and no history of diabetes. Clinical assessment of stroke severity indicated a NIHSS 
score of 23. A CT scan was consistent with ischaemic stroke; it shows no haemorrhage 
or new ischaemic changes. There are no other factors which would deter treatment.
Do you have any comments about this case?
Given the information presented above, would you
immediately offer thrombolysis to this patient?
Yes [ ]
No  [ ]
FIGURE 2 Sample patient vignette.
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Further components of the online survey
The online survey also included questions and measurement scales to collect information on participant
characteristics and traits (see Appendix 4 for the full survey). The following questions relating to the profile
of respondents were collected prior to the decision scenarios: age, sex and medical specialty, level of
experience (time in months) treating stroke patients, experience (time in months) administering intravenous
thrombolysis and willingness to control blood pressure before administering thrombolysis. Participants
were then randomly assigned to receive one of eight blocks of vignettes, where each block comprised
13 hypothetical patient vignettes. Following the presentation of the hypothetical vignettes, a series of
additional questions and scales were included to gather information on clinician characteristics of interest
that were hypothesised to influence thrombolysis decision-making. These are detailed below.
Institutional Culture Scale
For the purposes of the current research, in the absence of an available scale, a new scale was developed
(from existing measures where possible) to gauge the culture of thrombolysis and stroke care, and the
influence of colleagues at a respondent’s place of work. A six-item scale was collated to assess this
dimension and Table 8 includes the items used for this purpose. Items were scored on a 6-point Likert-type
scale from strongly disagree (1) to strongly agree (6). Factor analysis was conducted on this new scale and
a one-factor solution was obtained, representing institutional culture of thrombolysis. The results of the
complete results of the factor analysis are available in Appendix 5.
Attitude towards risk-taking
The risk-taking subscale of the Jackson Personality Inventory100 was employed. It is a six-item measure
that has been previously used in clinical decision-making research59,101 and measures attitudes towards
risk-taking. Scores were summed (reversed when appropriate) and, given that there were no missing data
on scale responses, a final risk-taking raw score was computed for each individual.
TABLE 8 Items included in Institutional Culture Scale
Item Adapted from
Most people whose opinion I value would approve of me treating a
patient presenting with acute ischaemic stroke within the 4.5-hour
time window with intravenous thrombolysis
Theoretical Domains Framework – social
influences scale item99
Prior to delivery of intravenous thrombolysis, clinicians are provided
with adequate training to inform decision-making regarding the
appropriate use of intravenous thrombolysis in the treatment of
patients with acute ischaemic stroke
Theoretical Domains Framework – environmental
influences and resources scale item99
We encourage internal discussion of patient care adverse events Practice Culture Scale66
There is an identifiable practice style that we all try to adhere to Practice Culture Scale66
My unit strongly encourages me to thrombolyse patients who meet
criteria for intravenous thrombolysis when presenting with acute
ischaemic stroke
New item created for this study
My unit does not hold meetings regularly to discuss and review stroke
service audit dataa
New item created for this study
a Item is reverse scored.
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Physician Reaction to Uncertainty scale
The Physician Reaction to Uncertainty scale was developed by Gerrity et al.60,61 to assess the impact
of affective uncertainty on clinicians. The scale has been widely used in medical decision-making
research60–62,102 and was employed to understand how respondents react to and deal with uncertainty in
their clinical practice regarding acute stroke care and decision-making about thrombolysis. Scores were
summed (reversed when appropriate) and, given that there were no missing data on scale responses,
a final raw score was computed for each respondent.
Questions relating to decision-making and experience of
administering thrombolysis
Clinicians were also asked to state the recency of their last decision made about patient suitability for
thrombolysis, how many patients they estimated they had thrombolysed in the past 12 months, how many
were harmed as a result of treatment in the past 12 months and how recently a patient was harmed as a
result of treatment with intravenous thrombolysis. These questions were aimed at assessing whether or not
recency and regularity of thrombolysis decision-making, and recency and frequency of negative outcomes
of thrombolysis, exerted an influence on decision-making about the offer of treatment. The recency of last
decision about thrombolysis and recency of harmful outcome as a result of administration of thrombolytic
treatment were transformed into total number of days for the purposes of the analyses.
Clinicians were also asked to state whether or not there was a formal acute stroke protocol for assessing
patient eligibility for thrombolytic treatment at their site of practice. A 6-point Likert scale was also used
to assess the impact of clinicians’ level of comfort treating a patient outside the licensing criteria on
thrombolysis decisions. Two final questions (6-point Likert scales) in the survey asked clinicians to rate their
level of comfort with communicating the risk/benefits of thrombolysis to patients (and/or family/carers)
and their perception of the evidence base for thrombolysis (i.e. whether or not respondents believe that
the evidence for treating acute stroke patients with intravenous thrombolysis is robust). Finally, participants
were debriefed and thanked for their participation.
The responses to the questions on clinician characteristics were analysed using appropriate descriptive
statistics.
Public/patient involvement in the research
Mr John Teah and Mr Stephen Simpson were the patient/public representatives on the Project
Management Group and have been actively engaged with the planning and design of the research since
the project began in June 2013. At least one patient representative attended each project management
meeting, with both patient/public representatives present at the majority of meetings. Project materials,
such as working document drafts and meeting agendas, were forwarded to all project management team
members for comments or suggestions ahead of scheduled meetings. This ensured that all team members
were clear on the topics for discussion and were provided with an opportunity to contribute on these
topics. As members of the Project Management Group, Mr Teah and Mr Simpson were involved in:
l advising on the design of the research
l approving and supporting the ethics application and providing feedback on the draft application
l providing feedback/input on drafts at all stages of the DCE development process and on drafts of
papers, reports and conference posters
l membership of the expert panel during study design discussions and ranking exercises
l advice on the promotion of the online survey and dissemination of results via links with the
Stroke Association
l planning for the codelivery of research findings at dissemination events to non-specialist audiences.
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Participant recruitment
We recruited clinicians via newsletter and e-mails sent through the professional associations of various
medical specialties involved in stroke care in the UK. This included BASP, the Society for Acute Medicine,
the College of Emergency Medicine, the British Geriatrics Society and the Association of British
Neurologists. An invitation to participate was also sent to the SITS co-ordinators in the UK and a notice
about the study was included as a news item on the SSNAP audit webpage. An invitation to participate,
together with an information sheet and a link to the survey, was distributed via these routes. The invitation
e-mail also stated that all respondents who finished the survey could be entered into an optional prize
draw to win a tablet computer. Although sampling through BASP would capture the great majority of
decision-makers on thrombolysis in the UK, we sought to extend our sample to take account of diversity
in how services are delivered in the UK (e.g. in some cases emergency department specialist physicians may
have independent responsibility for decision-making about thrombolysis) by also including other medical
specialties with responsibilities for thrombolysis decision-making.
In order to ensure eligibility for participation in the survey, a screening question was first provided to
participants asking if they were involved in the ‘final decision-making’ about the offer of thrombolysis for
patients with acute ischaemic stroke. If they did not have a role in the final decision-making, they were
screened out of the survey.
Data management and hosting of the online discrete
choice experiment
The market research company (Accent, Edinburgh, UK; www.accent-mr.com/) converted the DCE design
and survey into an online survey. The survey was live for 6 months from September 2014 to February
2015. Data were returned to the research team in an anonymised format and entered into Stata/IC13
for analysis (StataCorp LP, College Station, TX, USA).
Scripting error
On receipt of the data from the market research company, we identified that the programmers had made
some errors in the final application of scripting the online survey. This was thoroughly investigated and
we identified that, as a result, 10.3% of the vignettes included implausible combinations of patient
characteristics (e.g. severe dementia with pre-stroke dependency of mRS1 and severe dementia with NIHSS 2
with aphasia). We therefore ran models both with and without the erroneous vignettes and found little
difference in the results. We decided that our primary analysis would exclude the erroneous vignettes.
All analyses reported are on this basis.
Analytical plan
An a priori data analysis plan was developed to prioritise predictors for inclusion in a hierarchical approach.
To focus the enquiry, the expert panel ranked the variables (Figure 3 and Table 9). Models 1 and 2
specifically addressed study objectives 1 and 2 by examining which patient and clinician factors were
statistically significant predictors of decision-making regarding the offer of thrombolysis. Model 3 was used
to establish the additional variance explained by the remaining clinician factors.
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Model 1: to include all nine
patient-related factors 
in vignettes
Model 2: model 1 + top seven 
clinician factors based 
on ranking exercise
Model 3: models 1 and 2 + remaining 
clinician factors
FIGURE 3 A priori data analysis plan for inclusion of predictors in the analytical model.
TABLE 9 Results of the ranking exercise completed by the expert panel
Factor Mean rank SD Median
Interquartile
range
1. Perception of evidence base 3.3 2.5 3 7
Model 2
variables
2. Attitude towards risk 3.7 3.45 2 7
3. Comfort level treating patient outside licensing
criteria/not treating a patient within criteria
4 3.16 3 7
4. Number of patients harmed in past 12 months 5.3 1.51 5 4
5. Physician reaction to uncertainty 5.83 5.19 3 13
6. Time since most recent negative outcome
of rtPA
7.8 4.12 6 9
7. Number of patients thrombolysed in past
12 months
8.3 3.21 8 11
8. Number of years’ experience 9.3 5.75 11 14
Model 3
variables
9. Medical specialty 9.67 3.01 10 8
10. Willingness to control BP 10.8 2.99 11 8
11. Perception of institutional culture 11 4.86 10 13
12. Approximate thrombolysis rate 11.2 3.66 12 10
13. Service configuration of hospital 11.3 4.80 12 11
14. Confidence communicating risk information 11.3 5.24 12 13
15. Recency of last rtPA decision 11.8 3.43 11 10
16. Percentage of acute stroke patients
thrombolysed of those assessed
12.7 3.56 14 10
17. Location of hospital 17.2 0.98 18 2
18. Availability of rtPA protocol 17.2 2.32 18 7
19. Age 18.7 1.03 19 3
20. Sex 19.5 .55 19 1
BP, blood pressure; SD, standard deviation.
⎫⎟⎟⎟
⎬⎟⎟⎟⎭
⎫⎟⎟⎟⎟⎟⎟⎟
⎬⎟⎟⎟⎟⎟⎟⎟⎭
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Analyses conducted on the data set
Appropriate summary statistics were used to describe the sociodemographic profile and other
characteristics of the sample.
The data were modelled in a random utility theory framework using limited dependent variable modelling.
The binary decision to offer thrombolysis was modelled as a function of the levels of the variable patient
factors presented in the hypothetical vignettes and the characteristics of the decision-makers (the clinicians
responding the survey).
Mixed-logit regression analyses were conducted on the data. This facilitated the examination of
unobserved heterogeneity among respondents and accounted for the panel nature of the data. Further
details on the mixed-logit regression and the rationale for its use are included in Appendix 6. The intercept
[alternative specific constant (ASC) representing underlying preferences for treatment over no treatment,
all else constant] and model parameters are assumed to be random and normally distributed (mean and
standard deviations are reported). A positive coefficient for a level of a variable factor in the mixed-logit
regression models, compared with the reference level of the factor, represents a driver of a decision
to offer thrombolysis, whereas a negative coefficient represents an inhibiting influence on the decision to
offer thrombolysis (i.e. more likely not to offer treatment). p-Values of < 0.05 indicate whether or not the
coefficients are statistically significantly different from zero, and the odds ratios (95% confidence intervals)
are presented to enable the magnitude/precisions of the effect to be assessed. Effects coding was used
for all nine patient factors included in the DCE. Clinician factors were interacted with the ASC and then
entered in the model. Further information on effects coding, and the theory and formulae underlying
DCEs, is available in Appendix 6.
Independent covariates were interacted with the ASC to explore how preferences for offering treatment/
not offering thrombolytic treatment differed depending on the covariates (i.e. characteristics of the
decision-makers). Checks for multicollinearity were performed to ensure that predictor variables were not
highly correlated with each other. The Project Management Group agreed that if this occurred, decisions
on which variable to exclude/retain would be based on the criteria from the ranking exercise: that is those
variables that are most amenable to change and useful in the context of CPD/learning.
Data can be obtained from the corresponding author.
External validity
We compared a number of patient vignettes included in the DCE with national patient data to assess the
external validity of our findings. In consultation with SSNAP, six subsets of patient data were collated to
compare decision-making about thrombolysis in the current study with real-world decision-making for UK
patients admitted to hospital (or date of onset if already in hospital) between April 2013 and March 2015.
Six patient vignettes were chosen as they represented the extremes of decision-making observed in the
current study (high rates of offering and not offering thrombolysis, respectively) and were chosen to ensure
that vignettes were sufficiently different so that no one patient would appear in more than one of the
SSNAP data subsets.
However, SSNAP does not collect data for all patient factors examined in the current study (e.g. no
information on blood pressure, frailty or pre-stroke cognitive function). Furthermore, certain categories
of SSNAP data were extended to broaden the patient samples. For instance, decisions were made for the
practical reason of avoiding limiting the patient samples so as to make them overly specific. Therefore,
ranges were included for NIHSS score, patient age and onset to scan/decision time, and the vignette used
in the study is representative of a patient in these categories. In addition, no restriction was placed
on patient sex or ethnicity owing to the prohibitively small numbers that would have been observed in
the patient data subsets.
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Chapter 4 Results
Summary statistics for the sample
Table 10 presents a summary of the sociodemographic profile and other characteristics of the respondents
(n = 138). Respondents had a mean age of 46 years (range 30–68 years). The majority were male (73.2%)
and identified themselves as a stroke clinician. The average amount of experience treating acute ischaemic
stroke patients and administering intravenous thrombolysis was 132 months (11 years; range 3 months to
38 years) and 76 months (6 years 4 months; range 3 months to 22 years), respectively. The average time
taken to complete the online survey was 23 minutes.
Although no information is available on non-respondents to the online survey, the profile of the
respondents is broadly representative of the population of medical professionals involved in acute stroke
care in the UK. Based on data from the SSNAP acute organisation audit,103 the profile of the current
sample in terms of medical specialty is proportionately representative of those involved in decision-making
about thrombolysis; stroke clinicians are most often on thrombolysis rotas, followed in decreasing order by
geriatricians/care of the elderly physicians, neurologists, and accident and emergency (A&E) and acute
medicine physicians. Furthermore, the average age and sex split in the current sample is consistent with
data from the Royal College of Physicians (RCP) 2012 census.104 For example, there are more male
consultants than female consultants in the specialties of stroke medicine, acute medicine, neurology and
geriatric medicine (78%, 70%, 76% and 65%, respectively)104 and these proportions are reflected in the
current sample. Similarly, the average age of respondents in the current sample is consistent with RCP
census data.
Reliability analyses were conducted on the measurement scales employed in the survey. Following factor
analysis, the Institutional Culture Scale developed specifically for this research demonstrated a one-factor
solution. High scores on the scale represented a stronger institutional culture of thrombolysis.
Respondents’ scores ranged from –1 to 29 and the internal consistency was high with Cronbach’s alpha of
0.84. On the Jackson Personality Inventory risk-taking subscale, scores ranged from –14 to 9, with higher
scores indicating greater risk-taking. In the current study, the scale demonstrated good internal consistency
of 0.76. Finally, on the Physician Reaction to Uncertainty Scale, scores ranged from –12 to 39, with higher
scores indicating greater discomfort with uncertainty. In the current study, the scale demonstrated high
internal consistency of 0.81.
Overview of decision-making about offer of intravenous
thrombolysis
There was generic general preference not to offer treatment of intravenous thrombolysis to patients
described in the hypothetical vignettes overall (Table 11).
In total, nine participants responded that they would not offer treatment to patients in all of the vignettes
they were presented with. These participants were across a range of design blocks and included a range of
medical specialties and experience levels; experience treating patients with intravenous thrombolysis
among these participants ranged from 8 months to 10 years.
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TABLE 10 Characteristics of sample
Variables Mean (SD) n (%)
Age 45.83 (8.71)
Male 101 (73.2)
Medical specialty
Stroke 81 (58.7)
A&E 20 (14.5)
Geriatric medicine 17 (12.3)
Neurology 17 (12.3)
Acute care 3 (2.2)
Grade/seniority
Consultant 123 (89.1)
Staff doctor 6 (4.3)
Specialty trainee 7 (5.1)
Other 2 (1.4)
Experience with treating acute ischaemic stroke (months) 131.5 (99)
Experience with administering thrombolysis (months) 75.5 (43)
Willing to control blood pressure (when applicable) before thrombolysis 132 (95.7)
Formal protocol is available for assessing patient eligibility for thrombolysis 136 (98.6)
Service configuration
Consultant led 61 (44)
Combined telemedicine and consultant led 77 (56)
Risk-taking scale score –2.19 (5.33)
Physicians’ Reaction to Uncertainty Scale score 12.86 (9.39)
Institutional Culture Scale score 24.73 (5.24)
Perception of the evidence base for thrombolysis 4.67 (1.36)
Confidence communicating benefits/risks of thrombolysis 5.12 (1.02)
Number of days since last thrombolysis decision made 18 (38)
Number of patients thrombolysed by respondents in past 12 months 19 (15)
Number of patients harmed as a result of thrombolysis in past 12 months 0.8 (1.05)
Days since patient was harmed as a result of thrombolysis 408 (744)
A&E, accident and emergency; SD, standard deviation.
TABLE 11 Overview of decision-making about the offer of intravenous thrombolysis
Decision Frequency (%)
Offer thrombolysis 504 (31.4)
Do not offer thrombolysis 1103 (68.6)
Total 1607 (100)
RESULTS
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Discrete choice experiment regression results
All analyses were undertaken using Stata/IC13. Following adjustment of the data set (removal of implausible
combinations of pre-stroke dependency of mRS1 and severe dementia, and of severe dementia and NIHSS 2
with aphasia), there were 1607 observations of discrete decisions about the offer of thrombolysis.
To control for any possible effects of block in the design, seven dummy variables were also included in the
analyses (comparing each block with block 1) to control for potential differences between blocks. Where
significant differences emerged, these are reported in the results tables.
Model 1: patient-related factors
The results of the mixed-logit analysis for model 1 are presented in Table 12. The ASC is negative and
statistically significant, indicating a general preference not to offer intravenous thrombolysis, all else equal.
Compared with their reference categories (in brackets), four patient factors were statistically significant
predictors of decisions not to offer thrombolysis: (1) patient age of 95 years (68 years); (2) stroke symptom
onset time of 4 hours 15 minutes, proximal to the upper limit of 4.5 hours stipulated in the licensing
criteria for thrombolysis (50 minutes); (3) patients with severe dementia (no history of memory problems);
and (4) systolic blood pressure (SBP) values of 200 mmHg (140 mmHg).
There were also eight statistically significant predictors of decisions to offer thrombolysis (compared with
reference levels in brackets): (1) patient age of 85 years (68 years); (2) Afro-Caribbean ethnicity (white);
(3) stroke symptom onset time of 2 hours 30 minutes (50 minutes); (4) a pre-stroke dependency score of
mRS3 (mRS4); and (5) SBP values of 185 mmHg (140 mmHg). Compared with the stroke severity reference
category of NIHSS 2 (without aphasia), respondents were significantly more likely to offer thrombolysis to
patients with scores of NIHSS 5 (without aphasia), NIHSS 14 and NIHSS 23.
The standard deviation for the ASC is statistically significant suggesting there was considerable
heterogeneity among respondents in their thrombolysis decision-making. There was also substantial
heterogeneity on several of the random effects coefficients (i.e. the patient factor levels), with nine
standard deviations significant, indicating substantial variation between participants in their thrombolysis
decisions as a function of differing levels of patient-related factors; or put differently, the response to or
preferences in relation to particular attributes differed over clinicians.
Model 2: patient-related factors and prioritised clinician factors
Table 13 presents the results of the mixed-logit regression analysis for model 2, which includes the nine
patient-related factors and seven clinician characteristics added to the model as a way to explore observed
heterogeneity. These variables were prioritised for inclusion based on an a priori ranking exercise
conducted by the expert panel (see Chapter 3, Analyses conducted on the data set). The clinician variables
included were respondents’ perception of the evidence base for thrombolysis; Physician Reaction to
Uncertainty Scale score; clinicians’ attitude towards risk score; the number of days since a patient was
harmed as a result of treatment with thrombolysis; total number of patients thrombolysed in the past
12 months; comfort treating patients outside criteria; and number of patients harmed by thrombolysis in
the past 12 months.
Consistent with model 1, the ASC for model 2 is negative and statistically significant, indicating that there
was a general preference not to offer intravenous thrombolysis. The standard deviation for the ASC for
model 2 is also statistically significant, which indicates the presence of considerable heterogeneity among
respondents regarding their thrombolysis decisions. There was also considerable heterogeneity for the
random-effects coefficients (i.e. the levels of patient factors), with the standard deviations of 17 factor
levels emerging as statistically significant.
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TABLE 12 Model 1: summary of mixed-effects logit regression analysis for influence of patient factors/levels on the
clinical decision to offer intravenous thrombolysis
Factor Level Coefficient SE p-value Odds ratio (95% CI)
Patient age,
mean (SD)
68 Reference
85 0.71 (0.26) 0.26 (0.33) 0.005 (0.44) 2.03 (1.23 to 3.35)
95 –2.02 (0.71) 0.66 (0.27) 0.002 (0.01) 0.13 (0.04 to 0.49)
Patient ethnicity,
mean (SD)
White Reference
Asian –0.46 (0.23) 0.27 (0.28) 0.09 (0.41) 0.63 (0.37 to 1.08)
Afro-Caribbean 0.87 (0.09) 0.33 (0.42) 0.009 (0.82) 2.39 (1.24 to 4.58)
Patient sex,
mean (SD)
Male Reference
Female –0.32 (0.01) 0.44 (0.28) 0.463 (0.97) 0.73 (0.31 to 1.71)
Time since symptom
onset, mean (SD)
50 minutes Reference
2 hours 30 minutes 0.54 (0.61) 0.25 (0.72) 0.03 (0.40) 1.72 (1.05 to 2.81)
4 hours 15 minutes –1.54 (0.66) 0.31 (0.32) < 0.001 (0.04) 0.21 (0.12 to 0.39)
Patient frailty,
mean (SD)
Not frail Reference
Frail –0.26 (0.34) 0.19 (0.26) 0.0179 (0.20) 0.77 (0.53 to 1.12)
Pre-stroke
dependency (mRS
score), mean (SD)
mRS1 0.80 (–3.01) 1.05 (0.49) 0.447 (< 0.001) 2.23 (0.28 to 17.51)
mRS3 1.33 (0.39) 0.42 (0.34) 0.001 (0.24) 3.78 (1.67 to 8.6)
mRS4 Reference
Pre-stroke cognitive
status, mean (SD)
No history of
memory problems
Reference
Moderate dementia 0.29 (1.30) 0.31 (0.30) 0.349 (< 0.001) 1.34 (0.73 to 2.44)
Severe dementia –2.82 (0.11) 0.60 (0.30) < 0.001 (0.73) 0.06 (0.02 to 0.19)
SBP, mean (SD) 140 mmHg Reference
185 mmHg 1.17 (1.17) 0.36 (0.33) < 0.001 (< 0.001) 3.22 (1.7 to 6.11)
200 mmHg –5.19 (2.05) 0.77 (0.42) < 0.001 (< 0.001) 0.01 (0.00 to 0.02)
NIHSS score (stroke
severity), mean (SD)
2 (without aphasia) Reference
2 (with aphasia) 0.15 (1.20) 0.51 (0.53) 0.761 (0.02) 1.16 (0.43 to 3.14)
5 (without aphasia) 1.48 (0.33) 0.49 (0.59) 0.002 (0.57) 4.39 (1.69 to 11.38)
5 (with aphasia) 0.65 (2.56) 0.41 (0.60) 0.111 (< 0.001) 1.92 (0.86 to 4.28)
14 2.04 (0.39) 0.60 (0.51) 0.001 (0.45) 7.69 (2.35 to 25.13)
23 1.38 (1.15) 0.597 (0.52) 0.021 (0.03) 3.98 (1.23 to 12.84)
ASC, mean (SD) Decision to offer
thrombolysis
–5.46 (2.07) 1.03 (0.30) < 0.001 (< 0.001) 0.01 (0 to 0.03)
Block effects, mean Block 6 1.82 0.9 0.042
SD, standard deviation.
Log-likelihood = –610.642; likelihood ratio χ2(20)= 225.22; number of observations = 1583; 24 observations removed by
Stata for not contributing significantly to the model estimates. These observations related to individual respondents with
little or no variation in their thrombolysis decision-making, i.e. decided to treat/not treat for all cases or all but one case.
Akaike information criteria: 1275.29; Bayesian information criteria: 1420.2.
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TABLE 13 Model 2: summary of mixed-effects logit regression analysis for influence of patient factors/levels and
clinician factors on the decision to offer intravenous thrombolysis
Factor Level Coefficient SE p-value Odds ratio (95% CI)
Patient age, mean (SD) 68 Reference
85 2.99 (4.46) 1.04 (1.17) 0.004 (< 0.001) 19.89 (2.58 to 152.7)
95 –2.88 (2.95) 1.24 (0.83) 0.02 (< 0.001) 0.06 (0 to 0.64)
Patient ethnicity,
mean (SD)
White Reference
Asian –0.32 (2.06) 0.57 (0.58) 0.57 (< 0.001) 0.73 (0.24 to 2.22)
Afro-Caribbean 3.79 (2.78) 1.15 (0.84) 0.001 (0.001) 44.42 (4.69 to 422.06)
Patient sex, mean (SD) Male Reference
Female 1.62 (2.21) 1.07 (0.72) 0.13 (0.002) 5.05 (0.62 to 40.82)
Time since symptom
onset, mean (SD)
50 minutes Reference
2 hours 30 minutes 3.05 (0.91) 0.85 (0.43) < 0.001 (0.03) 21.12 (4 to 111.1)
4 hours 15 minutes –6.21 (3.72) 1.65 (0.98) < 0.001 (< 0.001) 0 (0.01 to 0.05)
Patient frailty, mean (SD) Not frail Reference
Frail 0.01 (0.03) 0.38 (0.35) 0.98 (0.94) 1.01 (0.48 to 2.14)
Pre-stroke dependency
(mRS score), mean (SD)
mRS1 3.08 (12.81) 1.76 (3.28) 0.08 (< 0.001) 21.76 (0.69 to 685.31)
mRS3 3.51 (3.04) 1.06 (0.88) 0.001 (0.001) 33.45 (4.11 to 271.11)
mRS4 Reference
Pre-stroke cognitive
status, mean (SD)
No history of
memory problems
Reference
Moderate dementia 2.87 (–1.81) 0.99 (0.59) 0.004 (0.002) 17.64 (2.5 to 125.76)
Severe dementia –8.07 (5.42) 1.97 (1.4) < 0.001 (< 0.001) 0.01 (0.01 to 0.02)
SBP, mean (SD) 140 mmHg Reference
185 mmHg 4.64 (6.98) 1.23 (1.79) < 0.001 (< 0.001) 103.54
(9.33 to 1158.2)
200 mmHg –17.51 (9.11) 4.1 (2.24) < 0.001 (< 0.001) 0 (0 to 0)
NIHSS score (stroke
severity), mean (SD)
2 (without aphasia) Reference
2 (with aphasia) –1.38 (3.82) 1.05 (1.43) 0.19 (0.01) 0.25 (0.03 to 1.97)
5 (without aphasia) 7.74 (2.41) 2.22 (1.24) < 0.01 (0.05) 2298.5
(29.4 to 178,688)
5 (with aphasia) 3.13 (11.84) 1.17 (2.89) 0.008 (< 0.001) 22.87 (2.29 to 227.3)
14 6.98 (3.39) 1.86 (1.11) < 0.001 (0.002) 1074.92
(28 to 41,386.5)
23 9.15 (0.37) 2.7 (0.89) 0.001 (0.68) 9414.44
(43.6 to 2,047,889)
Perception of
evidence base
0.55 0.29 0.053 1.73 (0.99 to 3.05)
Number thrombolysed in
past 12 months
0.21 0.05 < 0.001 1.23 (1.11 to 1.37)
Physician reaction
to uncertainty
2.46 0.89 0.006 11.7 (2.01 to 67.71)
Attitude towards risk 0.06 0.07 0.35 1.06 (0.93 to 1.22)
continued
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The pattern of results obtained in model 2 is broadly consistent with that of model 1 (see Table 12).
All of the statistically significant patient factor predictors of thrombolysis decisions from model 1 remained
significant contributors to the model; however, an additional two patient factors were statistically significant
predictors of decisions to offer thrombolysis: (1) moderate dementia and (2) NIHSS 5 (with aphasia).
Four of the seven clinician factors were statistically significant predictors of thrombolysis decisions.
Respondents’ were significantly more likely to offer thrombolysis when they (1) perceived the evidence
base for thrombolysis to robust; (2) had thrombolysed a high number of patients in the past 12 months;
and (3) reported a higher level of discomfort with uncertainty (assessed by the Physicians’ Reaction to
Uncertainty Scale). Finally, clinicians who reported being comfortable treating patients outside the licensing
criteria were significantly less likely to offer thrombolysis.
Comparison of the Akaike and Bayesian information criteria established that model 2 was a better fit than
both model 1 and model 3. The full results of model 3 are included in Appendix 7.
TABLE 13 Model 2: summary of mixed-effects logit regression analysis for influence of patient factors/levels and
clinician factors on the decision to offer intravenous thrombolysis (continued )
Factor Level Coefficient SE p-value Odds ratio (95% CI)
Number harmed by
thrombolysis in past
12 months
–0.48 0.52 0.36 0.62 (0.22 to 1.72)
Days since patient was
harmed by thrombolysis
0.01 0.001 0.48 1.01 (1 to 1.01)
Comfort treating
outside criteria
–0.78 0.34 0.02 0.46 (0.24 to 0.89)
ASC, mean (SD) Decision to offer
thrombolysis
–26.99 (7.17) 6.79 (1.82) < 0.001 (< 0.001) 0 (0 to 0)
Block effects, mean Block 2 5.2 1.76 0.01
Block 3 3.93 1.76 0.03
Block 5 6.81 2.16 0.01
Block 7 6.48 2.07 0.01
Block 8 4.91 1.89 0.01
SD, standard deviation.
Log-likelihood = –583.65; likelihood ratio χ2(20)= 227.81; number of observations = 1583; 24 observations removed by
Stata for not contributing significantly to the model estimates. These observations related to individuals with little or no
variation in their decision-making, i.e. answered in one way (i.e. to treat/not treat) in all or all but one case.
Akaike information criteria: 1235.29; Bayesian information criteria: 1417.77.
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Predicted probabilities
The predicted probabilities of offering thrombolytic treatment to patients described in each vignette (based
on model 1) are available in full in Appendix 8.
Predicted probabilities for decisions to offer thrombolysis ranged from 0% (vignette numbers 8, 10, 14, 18, 19,
27, 34, 39, 43, 47, 57, 59, 65, 68, 71, 87, 80, 96 and 97; total observed rate of offering thrombolysis = 0%
to 23.1%) to 99.86% (vignette number 70; total observed rate of offering thrombolysis= 100%).
Based on the utility values (using the coefficients from model 1), the vignette in which respondents were
most likely to offer thrombolysis was number 70, which included the following level specifications:
Age 95; female; white; 2 hours 30 minutes since symptom onset; no history of memory problems;
pre-stroke mRS3; NIHSS 14; systolic blood pressure 140 mm/Hg; who you do not perceive as frail.
The vignette in which respondents were least likely to offer thrombolysis was number 39, which included
the following specifications:
Age 85; male; white; 4 hours 15 minutes since symptom onset; moderate dementia; pre-stroke mRS4;
NIHSS 2 (without aphasia); systolic blood pressure 200 mm/Hg; who you perceive as frail.
Qualitative comments and data interpretation
Of the 138 respondents, 96 individuals commented on at least one hypothetical patient vignette. In total,
497 free-text comments were provided by respondents as reasons why they would, or would not, offer
thrombolysis to the hypothetical patients described in vignettes; for example:
The patient is already dependant, is at the edge of 4.5 hours and has a severe stroke. I would judge
potential benefit of tpa as low and risk of haemorrhage relatively higher.
Male, neurologist, vignette 7, thrombolysis not offered
Against–Age of 85, MRS 3 (relative contraindication, in my opinion), high NIHSS. For- symptom onset
<1 hr, BP 140, BM 6.
Male, stroke clinician, vignette 15, thrombolysis offered
To provide further insights into cognitive processes underpinning thrombolysis decisions, comments from
respondents for variable patient factors are summarised below, along with direct quotes to illustrate key
themes in these data.
Patient demographics (age, sex and ethnicity)
There were relatively few comments on patient sociodemographics (age, sex and ethnicity) as factors
influencing decision-making for patient vignettes. Several respondents stated that patient age
(independently) would not influence their decision-making about thrombolysis:
Age itself is not a barrier and within good time window to benefit; it rather depends on the
breakdown of the NIHSS categories.
Male, stroke clinician, vignette 83, thrombolysis offered
Age alone not a reason NOT to [thrombo-] lyse.
Male, stroke clinician, vignette 72, thrombolysis offered
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However, a large proportion of comments related to the interaction of patient age and onset time when
making thrombolysis decisions, in particular with reference to patients aged > 80 years and evidence
from IST-3:
I have been taught locally that due IST3 data suggesting benefit of rTPA after 3h in over 80s
is minimal.
Female, neurologist, vignette 12, thrombolysis not offered
The IST3 trial did not show benefit in treating patients over 80yrs beyond 3 hours.
Male, stroke clinician, vignette 80, thrombolysis not offered
No respondents made any comments about patient sex. Only two comments explicitly referred to patient
ethnicity in combination with other factors; specifically, the cultural background of Asian patients was
mentioned in both instances as drivers of decisions to offer thrombolysis, with references to beliefs about
cultural (familial) values and acceptability of palliative care in hospital:
Mobility and level of communication with family as well as participation in family life would be
important. Some Asian elderly people can do actually better to what ADLs [activities of daily living]
assessments are.
Female, stroke clinician, vignette 17, thrombolysis offered
IST-3 shows she could be safely treated; she is likely to be at home prior to this given her cultural
background and would wish to remain so; leaving her with this stroke may mean she needed a PEG
and/or institutional care which would not be in keeping with her culture?
Female, geriatric medicine physician, vignette 83, thrombolysis offered
Frailty
Patient frailty was not independently noted as a contraindication for treatment with thrombolysis, although
frailty in combination with other patient factors such as mild stroke and moderate/severe dementia (and
concomitant perception of increased bleeding risk) was frequently cited as a reason not to offer treatment.
Low NIHSS and high risk of bleeding as delayed presentation. Also frail. I feel the risk would be
too high.
Male, geriatric medicine physician, vignette 39, thrombolysis not offered
The patient is frail, dependent with a MRS of 4 and has a low NIHSS.
Male, geriatric medicine physician, vignette 16, thrombolysis not offered
Pre-stroke cognitive status
In vignettes where patients had moderate or severe dementia, many clinicians commented on the lack of
evidence (and uncertainty) about the efficacy of thrombolysis and on increased bleeding risks, including
concerns about the negative impact of severe dementia on the recovery process:
Evidence regarding safety of thrombolysis in dementia is lacking. Demented patient > 85 yrs may have
microbleeds. Given mRS of 4, and reduced likelihood of benefit from late treatment, I would assume
risk outweighs benefit.
Male, stroke clinician, vignette 7, thrombolysis not offered
Certainly not if moderate or severe small vessel changes on CT scan. If no such changes then perhaps:
but severe dementia a very limiting factor to recovery.
Male, stroke clinician, vignette 71, thrombolysis not offered
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I would perceive this frail patient at high risk of complications, although this may be balanced by the
early time frame and significant motor deficit. I know that because of his dementia, he will find rehab
difficult, so maybe thrombolysis is his best shot. I have easy rapid access to stroke physicians and this is
the sort of case we would manage together.
Male, A&E physician, vignette 54, thrombolysis not offered
History of severe dementia would deter me from thrombolysis in this case.
Female, geriatric medicine physician, vignette 45, thrombolysis not offered
Systolic blood pressure
Comments about this patient factor related to both measured blood pressure values and blood pressure
lowering. Regarding the latter, several clinicians would attempt to lower blood pressure (when it was
above the licensing criteria cut-off of 185 mmHg) and then reassess the patients’ suitability for treatment,
whereas others would offer treatment and simultaneously take steps to reduce SBP, although the
importance of fully informing patients/family about the increased risk of bleeding in these circumstances
was emphasised:
High BP but will treat and reassess.
Male, geriatrician, vignette 20, thrombolysis not offered
I would treat this BP first and if it came down easily I would lyse [thrombolyse] him with family assent.
Male, stroke clinician, vignette 53, thrombolysis not offered
After long discussion with patient and only when satisfied patient knows the risk. Would also
simultaneously treat blood pressure.
Male, A&E physician, vignette 69, thrombolysis offered
There was also a subset of respondents who indicated they would actively monitor the patient’s blood
pressure and delay treatment decisions until it was below the threshold stated in the licensing criteria.
These considerations were influenced by onset time, and were mentioned in patient vignettes only when
stroke symptom onset time was well within the 4.5 hours (i.e. either 50 minutes or 2 hours 30 minutes):
I would wait to see if the BP settled.
Male, stroke clinician, vignette 29, thrombolysis not offered
Might wait additional 15–30 minutes to check if SBP drops to criteria level before thrombolysis.
Male, stroke clinician, vignette 33, thrombolysis not offered
I would monitor SBP, ensure no pain, retention etc. but not pharmacologically lower immediately.
Male, geriatric medicine physician, vignette 22, thrombolysis not offered
Stroke severity score (National Institutes of Health Stroke Scale)
Respondents would be less willing to treat a patient with thrombolysis with mild stroke (NIHSS score of ≤ 5).
NIHSS being ‘too low’ to warrant treatment was often cited by respondents as the primary reason underpinning
their decisions not to offer thrombolysis to patients described in hypothetical vignettes. This may reflect
the lack of a specific minimum NIHSS cut-off being stated in the licensing criteria and a lack of robust
evidence for absolute benefit of treatment for very mild stroke:
NIHSS too low.
Female, geriatric medicine physician, vignette 30, thrombolysis not offered
Very mild stroke. No evidence substantial gains to be had from TPA.
Male, neurologist, vignette 13, thrombolysis not offered
DOI: 10.3310/hsdr05040 HEALTH SERVICES AND DELIVERY RESEARCH 2017 VOL. 5 NO. 4
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Thomson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
39
However, some clinicians commented that low NIHSS with aphasia may influence their decision to offer
treatment, as they considered aphasia a ‘significant deficit’ that would impact negatively on quality of life
(which trumped low NIHSS scores).
Although NIH low, aphasia very disabling, potentially will mean significant change in social and
functional status. Not bothered by age.
Female, geriatric medicine physician, vignette 30, thrombolysis offered
I don’t use age as a criteria - she has some dependency but not the severest level. This is not a mild
stroke – aphasia if long lasting could make a big difference to her care requirements.
Male, stroke clinician, vignette 23, thrombolysis offered
At the higher NIHSS scores, even though respondents were cognisant that patients with high NIHSS scores
were significantly more likely to have a poor outcome from thrombolysis, clinicians were more likely to
offer treatment based on considerations that they had more to gain from treatment:
At higher risk of poorer outcome due to high NIHSS but time of onset within original NINDS 3 hour
window so would thrombolyse.
Female, neurologist, vignette 21, thrombolysis offered
I would explain that the chances of a good outcome are lower than usual but she has had a very
severe stroke and has little to lose.
Male, stroke clinician, vignette 35, thrombolysis offered
Severe Stroke. Little to lose from Rx[treatment].
Male, stroke clinician, vignette 60, thrombolysis offered
Pre-stroke dependency (modified Rankin Scale)
The influence of pre-stroke dependency on thrombolysis decision-making was variable. Patients’ pre-stroke
dependency was described by some clinicians as a contraindication for treatment when the mRS score was
3 or 4. This may reflect modest inter-rater reliability of mRS assessments (κ < 0.5)105 and considerations
about quality of life that may trump mRS assessments. Indeed, several clinicians commented that they
would not rely on mRS alone in their assessment of quality-of-life gains from treatment and risk–benefit
ratios for individual patients.
mrs = 3
Male, neurologist, vignette 59, thrombolysis not offered
MRS 4 risk > benefit
Male, neurologist, vignette 85, thrombolysis not offered
Too high level of dependency is primary reason for not thrombolysing
Male, A&E physician, vignette 27, thrombolysis not offered
mRS doesn’t tell the whole story so I would want to get a quick chat with family or carer to get a
clearer picture of QOL. If appropriate based on this discussion I would lyse [thrombolyse]
Male, stroke clinician, vignette 35, thrombolysis offered
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Symptom onset time
Early presentation/symptom onset time was a key driver of decisions to offer thrombolysis (which reflects
robust evidence of increased benefit from earlier treatment) and other potential contraindications were
traded off (such as severe stroke and mRS score of > 2) against the potential benefit of early treatment.
In these cases clinicians were willing to give patients the ‘benefit of the doubt’, as such patients were
considered to have ‘little to lose’.
This is a severe stroke with a very poor outcome. She has nothing to lose from treatment particularly
as she can be treated early in time window.
Male, stroke clinician, vignette 15, thrombolysis offered
Very early presentation and therefore maximal likely benefit (& normal BP - probably less likely to
bleed) in patient with significant speech defect probably will justify the treatment even with less than
favourable premorbid state.
Male, stroke clinician, vignette 23, thrombolysis offered
With early presentation benefit probably outweigh concerns about premorbid state.
Male, stroke clinician, vignette 74, thrombolysis offered
However, when symptom onset was 4 hours 15 minutes (approaching the upper end of the treatment
time window for thrombolysis) clinicians were reluctant to offer treatment in the context of other factors
that would indicate a higher risk of bleeding/poor treatment outcome.
The time factor is important and it is 4 hours 15 minutes + the NIHSS of 2 would not persuade me
to thrombolyse.
Male, stroke clinician, vignette 39, thrombolysis not offered
Time since symptom of onset is quite long and if true would decrease the likelihood of benefit from
thrombolysis. Would discuss with consultant/seniors but my inclination would be not to thrombolyse.
Female, neurologist, vignette 35, thrombolysis not offered
Consult with colleagues or patient/family
There were many instances in which respondents would consult with colleagues in stroke medicine and/or
engage the patient or family/carer in shared decision-making before making a final decision about
thrombolysis, especially for cases at the extremes (grey zone) of the licensing criteria. Several respondents
also expressed a wish to enquire further about the patient’s living status (nursing home or otherwise) in
order to inform their thrombolysis decisions:
This is one I would discuss with a stroke physician. I would consider the patient to have high vascular
fragility and at risk from complications. However, this patient has a significant disability. This is a case
for shared decision making.
Male, A&E physician, vignette 23, thrombolysis not offered
Approaching the end of the longer 4.5 hour time window therefore I would discuss with consultant
covering stroke whether their practice would be to thrombolyse or not.
Female, neurologist, vignette 50, thrombolysis not offered
I would discuss with family. She could be a good candidate but needs a best interest assessment given
low NIHSS and high premorbid disability.
Female, neurologist, vignette 95, thrombolysis not offered
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External validity
We compared a number of patient vignettes included in the DCE with national patient data. In
consultation with SSNAP, six subsets of patient data were collated to compare decision-making about
thrombolysis in this study with decision-making for UK patients admitted to hospital (or date of onset if
already in hospital) between April 2013 and March 2015. Six vignettes were chosen as they represented
vignettes at extremes of decision-making observed in the study (high rates of offering thrombolysis and
high rates of not offering thrombolysis) and were purposively chosen to ensure no overlap between SSNAP
data subsets (i.e. a patient from SSNAP database could qualify for inclusion in only one data subset).
Table 14 displays the features of the comparison between thrombolysis decisions made for patient
vignettes in the DCE and SSNAP data subsets. For many of the data subsets, similar patterns are evident
for treatment rates observed in practice in the UK and decision-making about the offer of thrombolysis in
the current study. There is typically a lower treatment rate in practice than the rates of offering treatment
in the current study; this was anticipated given that patients may be not be deemed eligible for treatment
owing to other complications and comorbidities.
TABLE 14 External validity check using SSNAP national patient data
Variable
Data subset 1
(vignette #70)
Data subset 2
(vignette #39)
Data subset 3
(vignette #10)
Data subset 4
(vignette #15)
Data subset 5
(vignette #83)
Data subset 6
(vignette #58)
Patient age
range (years)
90–100 80–90 63–73 80–90 90–100 63–73
Patient sex Male/female Male/female Male/female Male/female Male/female Male/female
Onset to scan/
decision time
(hours:minutes)
1:45 to 2:45 3:15 to 4:15 3:15 to 4:15 0:30 to 1:30 0:30 to 1:30 1:45 to 2:45
Pre-stroke
dependency
(mRS score)
3 4 4 3 4 4
NIHSS score 12–16 1–4 1–4 21–25 1–4 3–7
Patient ethnicity No restriction No restriction No restriction No restriction No restriction No restriction
Total number of
patients matching
criteria in SSNAP
51 36 11 68 6 19
Number (%) of
patients treated
with thrombolysis
in SSNAP
18 (35.3) 1 (2.7) 0 (0) 39 (57.4) 0 (0) 4 (21.1)
% who offered
thrombolysis in
current study
100 0 0 100 69.2 39.1
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Chapter 5 Discussion
Summary of key findings
This is the first DCE to explore patient- and clinician-related factors that influence the decision to offer
intravenous thrombolysis to patients with acute ischaemic stroke. Analysis of the DCE data revealed a
strong aggregate level preference not to offer thrombolytic treatment, which was expected given that the
vignettes were specifically designed to elucidate the influence of factors on decisions related to the ‘grey’
areas of the current licensing criteria for treatment.
Levels of seven different patient-related medical and non-medical (sociodemographic) factors [patient age,
patient ethnicity, stroke symptom onset time, pre-stroke dependency, SBP, stroke severity (NIHSS) and
pre-stroke cognitive status] and four different clinician-related ‘psychosocial’ factors (perception of
the evidence for thrombolysis, number of patients thrombolysed in the past 12 months, comfort with
uncertainty and comfort with treating patients outside the licensing criteria) were significant predictors of
an increased likelihood of decisions to offer or not offer thrombolysis (Table 15).
TABLE 15 Summary tables of DCE analysis results: drivers and inhibitors of decision-making about
intravenous thrombolysis
Variables
Drivers (increased likelihood of
offering thrombolysis)
Inhibitors (decreased likelihood
of offering thrombolysis)
Patient age (years) 85 (compared with 68) 95 (compared with 68)
Patient ethnicity Afro-Caribbean (compared with white)
Stroke symptom onset time 2 hours 30 minutes (compared with
50 minutes)
4 hours 15 minutes (compared
with 50 minute)
Pre-stroke dependency (mRS score) 3 (compared with 4)
SBP (mmHg) 185 (compared with 140) 200 (compared with 140)
Stroke severity (NIHSS score) 5 (with and without aphasia), 14 and 23
(compared with NIHSS 2 without aphasia)
Pre-stroke cognitive functioning Moderate dementia (compared with no
history of memory problems)
Severe dementia (compared with
no history of memory problems)
Perceived robustness of the evidence
base for thrombolysis
High
Number of patients thrombolysed in
the past 12 months
High
Discomfort with uncertainty
(physician reaction to uncertainty
scale)
High discomfort with uncertainty
Clinicians’ comfort with treating
patients outside the licensing criteria
High comfort with treating
patients outside the licensing
criteria
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Interpretation of results in relation to the literature
Patient age
Patients aged 95 years were significantly less likely to be offered treatment than patients aged 68 years.
Respondents were also significantly more likely to treat 85-year-olds than patients aged 68 years. The
benefits of thrombolysis for older patients in terms of reduction in disability is at least as great as those for
younger patients, despite an increased risk of sICH. Patients aged 85 years have more to gain from
treatment than younger patients (irrespective of risk) and this would also reflect acceptance of IST-3 data
that report benefit for patients aged > 80 years, in particular for those with onset to treatment time of
< 3 hours (the cut-off stated in the licensing criteria and the upper age limit in trials) and increased
recognition that chronological age does not necessarily equate to physiological age.106 That respondents
were more likely to treat 85-year-olds than 68-year-olds could indicate that, all things being equal,
clinicians may be more willing to risk a potential negative outcome of thrombolysis in 85-year-old patients
than in younger patients. Based on the results and qualitative data, it appears that clinicians are not
disinclined to treat older patients until those patients reach higher ages (≈95 years). It may also indicate
that clinicians are more likely to give the ‘benefit of the doubt’ to older patients and avoid denying
treatment based on age. It is also feasible that a social desirability effect has been observed, whereby
respondents may be overcompensating to avoid denying treatment based on age.
However, disinclination to treat patients aged 95 years may represent the upper limit of data from IST-3 or
reflect clinical practice or experience (there are few patients who have been treated in this age range in
routine practice). For instance, SITS data indicate that only approximately 10% of treated patients were
older than 80 years106,107 and Stroke Improvement National Audit Programme data indicate that only 2.5%
of the total number of patients who received thrombolysis between April 2010 and November 2011 were
older than 90 years.108
Time since symptom onset
Regarding the ‘time since symptom onset’ factor, consistent with expectations and strong evidence
of increased benefit with earlier treatment,16 we identified a statistically significant decreased likelihood of
offering treatment to patients who could be treated at 4 hours 15 minutes from symptom onset compared
with 50 minutes from symptom onset. The former is at the extreme end of the licensing criteria, and, given
the time dependency of the outcome, and that onset to treatment is estimated, would account for this
time period being an inhibitor of decisions to offer treatment. Clinicians were significantly more likely to
treat patients at 2 hours 30 minutes than at 50 minutes. This could indicate that clinicians have not been
in this situation very often because acute stroke presentations typically occur later than this, and it may be
that clinicians wait a short time in some borderline cases to see if the symptoms spontaneously improve.
This may indicate that some clinicians are willing to delay the final decision about thrombolysis if there are
some factors which create uncertainty; for instance, in mild stroke when a patient’s symptoms are rapidly
improving, the clinician may delay to see if symptoms resolve (per licensing guidelines45) or to potentially
give blood pressure time to stabilise or to take more readings before making a final decision about the
patient’s eligibility for thrombolytic treatment.109–111 This is in spite of research which confirms that earlier
treatment is associated with substantially more favourable outcomes,16 particularly when treatment occurs
within the ‘golden hour’ (< 60 minutes from symptom onset),110 and that delaying treatment owing to
perceived patient improvement or in the case of minor stroke could still risk significant disability
or death.111
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Stroke severity score (National Institutes of Health Stroke Scale)
Respondents were significantly more likely to offer thrombolysis to patients with severe strokes (NIHSS 14
and NIHSS 23) and to not offer thrombolysis to patients with mild stroke. This finding reflects the lack
of data on and uncertainty about the benefit of treatment of minor stroke and about poor outcomes for
patients with severe strokes. There was significant heterogeneity among respondents on the influence of
NIHSS 2 with aphasia and NIHSS 5 without aphasia. This implies that clinicians differ in their thresholds for
treatment of minor stroke and may also differ when considering the gains in quality of life for individual
patients with isolated language difficulties.
Patient ethnicity
Compared with white patients, Afro-Caribbean patients were significantly more likely to be offered treatment,
although there was no effect for Asian ethnicity. This is contrary to US-based research which found that
African American and minority patients were significantly less likely to receive thrombolytic treatment for acute
ischaemic stroke.112,113 Although efforts were made to exclude any diagnostic uncertainty, these findings may
be related to a perception of increased diagnostic certainty of stroke, given the evidence of increased rates
among this ethnic group. However, social desirability bias may help to account for the findings, with clinicians
overcompensating to avoid being seen as denying treatment based on race.
Pre-stroke dependency (modified Rankin Scale)
Patients with pre-stroke dependency of mRS3 (moderate disability: requiring some help, but able to walk
without assistance) were more likely to be offered treatment than those with mRS4 (moderately severe
disability: unable to walk without assistance and unable to attend to own bodily needs without assistance),
but mRS1 (no significant disability despite symptoms) was not significantly associated with thrombolysis
decision-making. We would have expected that respondents would be more willing to treat patients
with mRS1 than those with mRS4; however, the failure of this to reach significance may be due to an
imbalance between the levels of pre-stroke dependency in the study. Vignettes including mRS1 were
under-represented and therefore may have reduced the power to adequately compare these levels.
Pre-stroke cognitive status
Patients presenting with severe dementia were significantly less likely to be offered thrombolysis in models
1 and 2, with moderate dementia emerging as significant in model 2, indicating that clinicians were more
likely to offer thrombolysis in these cases (compared with patients with no memory problems). Inspection
of the standard deviations reveals significant variation between respondents on the influence of both
moderate and severe dementia on thrombolysis decision-making. This again emphasises that clinicians are
weighing up the pros and cons of treatment with reference to individual patient characteristics that are not
part of the licensing criteria, although it may also reflect perceptions that dementia increases risk of sICH,
which is contrary to research demonstrating no increased risk.114 In the comment boxes after the vignettes,
many respondents expressed that they would seek to discuss the risks and benefits of treatment with the
patient’s family/carer or seek further information about living status/dependency level prior to making a
final decision about the offer of treatment. It was also noted that patients with dementia may find
recovery/rehabilitation more difficult and, therefore, in some instances, thrombolysis may be worth the
risk in order to give the patient the best chance of regaining his or her pre-stroke quality of life.
Systolic blood pressure
Patients presenting with SBP of 200 mmHg were significantly less likely to be offered treatment than those
presenting with SBP of 140 mmHg. Given that this level is outside the licensing criteria for treatment with
thrombolysis, this is not surprising. However, results revealed that clinicians were more likely to offer
thrombolytic treatment when SBP was 185 mmHg (compared with the reference category of 140 mmHg).
This finding was surprising and no clear explanation was suggested for this in the comments. It may be
that once clinicians make the decision to attempt to reduce blood pressure, the decision to treat with
thrombolysis is reinforced. Thus, the decision to lower blood pressure may become interlinked with the
decision to offer thrombolysis, increasing the likelihood of thrombolysis being offered if attempts are made
to reduce blood pressure.
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Clinician factors
Four of the seven clinician factors ranked a priori as potential significant influences on decision-making
emerged as significant. There was a significant association found between the respondents’ perception of
the evidence base and the offer of thrombolysis. Although the mean score for perception of the evidence
was high, suggesting that the majority of respondents considered the evidence robust, those who
perceived the evidence as more robust were more likely to offer treatment.
The Physician Reaction to Uncertainty scale60,61,102 has been demonstrated to influence diagnostic
decision-making and, in the current study, higher discomfort with uncertainty was associated with
increased likelihood of offering thrombolysis. This may indicate a preference for action over inaction in
instances of high uncertainty, or what may be termed commission bias.54 Commission bias is defined as
the tendency towards action/intervention rather than inaction.54 Given the high scores observed on
the Institutional Culture Scale in the study, indicating a strong culture of administering thrombolysis in
respondents’ institutions, clinicians may worry more about decisions not to treat and therefore those with
higher levels of discomfort with uncertainty may be more willing to thrombolyse patients. Clinicians who
experience high discomfort with uncertainty may be more likely to offer thrombolytic treatment to patients
if it is perceived as the dominant or favoured position among colleagues or peers.
The results also indicated that clinicians who reported being more comfortable treating patients outside
the licensing criteria were less likely to offer treatment in the current study; however, we do not have a
clear explanation for this finding.
Finally, there was a significant association between clinicians’ experience of thrombolysis and the likelihood
of offering thrombolysis in the current study. This may indicate that familiarity with administration of the
treatment (and positive outcomes) increases likelihood of future use, and has important practical
implications for how clinicians are supported when they begin involvement in decision-making about
thrombolysis. Alternatively, it may simply represent the fact that those more likely to offer treatment in the
DCE are more likely to offer treatment in practice, and therefore have higher reported treatment rates.
Strengths and limitations
A key strength of this study is the use of a systematically developed and clinically valid DCE embedded
within an online survey. The DCE development process is clearly documented using a systematic, rigorous
and iterative process involving a multidisciplinary team to derive the optimal number and type of factors,
factor levels and associated operational definitions for inclusion in the DCE. It builds on ISPOR
guidelines77,78 by proposing and providing explicit guidance on a five-stage process, which may be
particularly beneficial when there is little or no previous research to guide DCE design in terms of optimal
format for presenting choice sets and selection of factors for inclusion to maximise utility of the findings.
This transparency in the development process of a DCE (process validity) to understand the decision
of interest (decision to offer thrombolysis or not) as well as information used by clinicians in their
decision-making and presentation of choice sets in a familiar format (patient vignettes), confers confidence
in the rigour and reliability of our findings and applicability to the real-world (ecological validity).28 Our
exploratory work to inform the design of the DCE indicated that individual clinicians often varied in the
cut-offs they employed for various factors in their decision-making about thrombolysis (e.g. blood pressure,
pre-stroke dependency level). Given this variance, we aimed to explore and better elucidate these grey
areas/areas of uncertainty in decision-making. Yet, as with most DCEs, a limitation is the fact that we
had to exclude some factors to make the survey possible. However, this was counterbalanced to some
degree by the inclusion of fixed factors, which allowed for the minimisation of extraneous influences on
decision-making, insofar as this was possible.
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Another strength of the analysis was our ability to account for both observed heterogeneity among
respondents (via inclusion of clinician factors in the model) and unobserved variation (via the estimation of
random parameters for the ASC and factor levels) using the mixed-logit regression.
Although we originally anticipated a sample size of 150–200 participants, our final sample (n = 138)
represents a good response rate in terms of the total population of clinicians involved in the final
decision-making regarding thrombolysis for acute ischaemic stroke patients in the UK (≈450–500).
Furthermore, the RCP census data suggest that our sample is representative of the demographic profile of
clinicians involved in stroke care in the UK. Observed response rates of clinicians involved in stroke care
were also similar previous online studies in the field of stroke medicine115,116 and similar to response rates
for other DCEs exploring clinical decision-making.117–120
As no linear variables were included in the analysis, we could not perform analysis that was originally
intended to investigate trade-offs in decision-making (marginal rates of substitution). The inclusion of
factors such as age and SBP as linear variables was investigated but preliminary analysis revealed that their
inclusion as linear would have masked the associations observed between various levels.
Key learning points and implications for research, training
and practice
Our research offers an important contribution towards a deeper understanding of the factors that
influence the decision to offer intravenous thrombolysis to patients with acute ischaemic stroke, in
particular factors that influence decisions for patients who fall within the grey zone of the licensing criteria.
The prohibitively long list of influential factors identified during stage 1 of the DCE development process
underscores the need for further research to explore the influence, if any, of factors not explored in this
study. For example, in acute stroke, patients on warfarin (and their associated anticoagulation/international
normalised ratio status), recent surgery/bleeding and comorbidities are factors likely to influence
thrombolysis decision-making and warrant future research.
As predicted based on SSNAP data,12,13,19 there was significant variation between clinicians in their
decision-making about thrombolysis for ‘grey’ cases. Our findings indicate that factors underpinning this
uncertainty in decision-making include medical factors, such as patients presenting with minor strokes, and
those at the upper limit of the stroke treatment window (where there is insufficient evidence of the benefit
of thrombolysis or where there may be uncertainty about the existing evidence).17
The results also raise an important issue regarding the treatment of patients who would be deemed ineligible
for treatment based on the current licensing criteria. For instance, several of the hypothetical patients
described in the vignettes would be considered outside the licensing criteria and would thus be excluded from
most major clinical trials (e.g. vignettes 11 and 23), and yet many participants in the study reported that they
would offer treatment in these scenarios. The Medicines and Healthcare products Regulatory Agency, in their
conclusions following the review of the evidence for thrombolysis,39 have cited several areas of the licensing
criteria that should be reviewed to determine whether or not the product guidelines accurately reflect the data
(e.g. age, the benefits/risks of thrombolysis in minor and major stroke). Clinicians make decisions about
whether or not to give thrombolysis based on perceived risks and benefits of treatment for that individual.
Participants in research studies are a clearly defined group who are not always representative of people with
stroke. There are relative and absolute contraindications for intravenous thrombolysis and the questions asked
by clinicians at the point of treatment decision-making are about the potential benefits and potential risks of
treatment for an individual patient. Previous research has underlined that considerable variation can exist even
among expert clinicians,20 and that experience and opinion (and probably other individual factors) rather than
just the licensing criteria affect decision-making and the perception of a patient’s eligibility for treatment.
The utility of decision support tools should be further explored to enable and support clinicians to make better
decisions around patient eligibility for treatment.79
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The finding that respondents were less likely to treat milder strokes (NIHSS score of < 5) might reflect the
lack of data/uncertainty around the benefit of treatment of minor stroke. It may be important to highlight
language impairment after stroke as an important factor in reduced social participation and quality of life
after stroke.121–123
As reported by previous research,50,51 the personal values, attitudes and beliefs of clinicians may influence
thrombolysis decision-making. Psychological and social factors are fundamental influencers of cognition
and behaviour (decision-making) and therefore education around the interactional nature of medical and
non-clinical influences on decision-making (biases) should form a part of clinical training. Research
indicates that although clinicians working in acute settings acknowledge the importance and relevance of
decision-making, there is little training or pursuit of theoretical learning on the topic.124 Croskerry et al.
have outlined the relevance of cognitive debiasing strategies for medical professionals and the importance
of embedding such strategies in training and CPD to avoid cognitive errors.63,125,126 Studies have found that
cognitive biases associated with intuitive judgments may be remedied by analytical reasoning.127,128 Thus,
decision support tools that facilitate the mapping and visualisation of risk and benefit79,129 for individual
patients may help to counteract intuitive-based biases or misperceptions, as well as assist in better
communicating evidence to patients, family and carers.130
Training and CPD should emphasise benefit of treating up to the 4.5-hour limit and the importance of
treating early and not delaying decision-making, as research illustrates a great proportional benefit with
early treatment when there are no contraindications for thrombolysis.15,34 Finally, this study indicates that
more experience of administering thrombolysis was associated with a greater likelihood of offering it.
This is indicative of the importance of developing practical learning and increasing exposure to intravenous
thrombolysis early in training to maximise appropriate delivery and build practitioner confidence and
self-efficacy in the administration of intravenous thrombolysis. Similarly, familiarity with the evidence base
for thrombolysis is crucial and should be a prerequisite for participation in thrombolysis rotas.
Key learning points and implications for discrete choice
experiment methods
Our study highlights the importance of an iterative design process for augmenting the clinical face validity
of the choice task in terms of (1) mode of administration (paper-based or electronic); (2) identification and
optimal selection of variable and fixed factors and associated levels to include in choice sets; (3) form of
choice set presentation (textual vs. traditional tabular approach, and order of information presentation);
and (4) the necessity of piloting to augment clinical face validity, and in turn external validity, and
acceptance of choice sets by the target population, prior to the data collection phase.
Key advantages of hosting a DCE online include facilitating access to large numbers of participants who
are geographically distributed; enabling respondents to complete a DCE survey at a time convenient for
them; and the option of completing in multiple sessions in different locations by providing a save-and-
return-later facility. Owing to the unpredictable working hours of clinicians in the NHS, it was important to
include these options.
Recommendations for future research
The nature of DCEs demanded that only a subset of potentially influential factors on clinical decision-making
could be explored in this research. Factors not investigated in this study warrant future research to
understand their impact, if any, on the decision to offer intravenous thrombolysis. The long list of potential
factors identified during stage 1 of the DCE development process underscores the range of patient factors
that may act as potential influences on thrombolysis decision-making.
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As no linear variables were included in the current analysis, we could not perform the analysis that was
originally intended to investigate trade-offs that clinicians make in decision-making (marginal rates of
substitution). The inclusion of factors such as age and SBP as linear variables was investigated but
preliminary analysis revealed that their inclusion as linear would have masked the associations observed
between various levels. Based on the qualitative results, it was clear that there were often multiple
interacting factors influencing decision-making in individual cases and therefore future studies should seek
to explore these trade-offs. In addition, exploring models accounting for attribute cut-offs may be a fruitful
avenue for future research.131
Further research is required in order to fully understand how clinician characteristics, beyond those
examined here, may impact on decision-making, and the most effective interventions for addressing
cognitive biases that may inhibit appropriate (and inappropriate) use of thrombolysis. Further work should
explore the influence of decision support tools that utilise evidence-based graphical depictions of risk and
benefit for individual patients on clinical decision-making and patient outcomes.
Strategy to translate findings into continuing professional
development/learning and training
A range of dissemination activities are planned to ensure that the results of the research are translated into
learning and will influence training and practice:
l National Stroke Thrombolysis Masterclass for clinicians. An accredited CPD training event for clinicians
involved in treatment of stroke patients took place on 16 October 2015 and an audience of
approximately 120 attended. Results of the study were presented, along with an interactive discussion/
voting session using patient vignettes from the research and results of decision-making from the study
to generate discussion. Dissemination booklets were also provided to attendees.
l Presentations at national and international conferences. Conferences targeted will include those on
shared decision-making and evidence-based practice, health psychology, medical decision-making,
stroke and emergency medicine. This will ensure that the results are disseminated widely to relevant
medical specialties and research groups.
l Dissemination event with the Stroke Association to present results to a public and patient audience.
l Report to the Intercollegiate Stroke Working Party with summary of findings and recommendations for
SSNAP audit data collection.
l A summary report of the results will be forwarded for inclusion in the newsletters of the professional
bodies through which we recruited participants and in the Stroke Association bulletin.
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Chapter 6 Conclusions
l This is the first DCE to explore factors that influence the decision to offer intravenous thrombolysis to
patients with acute ischaemic stroke using vignettes specifically designed to elucidate the influence of
factors on decisions related to ‘grey’ areas/areas of uncertainty in the licensing criteria/evidence.
l This research has documented the iterative process of DCE design, an element lacking in most
published DCE work in the field of clinical/medical decision-making.
l Findings from this research indicate that statistically significant predictors of not offering thrombolysis
are (reference categories in brackets) patient age of 95 years (68 years), SBP of 200 mmHg
(140 mmHg), symptom onset time approaching the upper limit of the time window for treatment at
4 hours 15 minutes (50 minutes), and pre-existing severe dementia (no history of memory problems).
l The analysis found statistically significant positive influences on decisions to offer thrombolysis which
were in line with previous research or supported by qualitative comments from respondents (compared
with reference categories in brackets): 2 hours 30 minutes since symptom onset time (50 minutes),
pre-stroke dependency of mRS3 (mRS4), and NIHSS scores of 5 without aphasia, NIHSS 14 and
NIHSS 23 (all compared with NIHSS 2 without aphasia).
l Further statistically significant positive influences on decisions to offer thrombolysis were found but
these were unexpected findings for which we do not have clear explanations: age 85 years,
Afro-Caribbean ethnicity (white) and SBP of 185 mmHg.
l There was evidence of significant heterogeneity among respondents in terms of overall decision-making
and heterogeneity in terms of the influence of levels of patient factors on decision-making. Among the
levels producing the most significant unobserved heterogeneity in decision-making were patient age
of 95 years, SBP of 185 mmHg and 200 mmHg, moderate dementia and NIHSS 5 with aphasia.
l Clinician-related factors also had a significant influence on thrombolysis decision-making (what the
literature refers to as observed heterogeneity); those who perceived the evidence for thrombolysis as
robust were more likely to offer thrombolytic treatment and those who reported higher rates of
thrombolysing patients in the past 12 months were more likely to offer thrombolysis.
l Two further clinician-related factors also influenced decision-making but require further research to
clarify and explain these finding. First, clinicians who reported a higher discomfort with uncertainty were
more likely to offer thrombolysis, perhaps indicating a preference for treatment over non-treatment in
instances of uncertainty, potentially influenced by the strong institutional culture of thrombolysis
observed. Second, the results indicate that clinicians who reported being more comfortable treating
patients outside the licensing criteria were less likely to offer treatment in the current study; however,
we do not have a clear explanation for this finding.
l Training and CPD programmes for stroke care and intravenous thrombolysis should address the impact
of non-medical influence on decision-making, impart cognitive debiasing strategies to optimise and
support decision-making, and should ensure clinicians develop practical learning and self-efficacy in the
administration of intravenous thrombolysis early in training and practice to maximise appropriate
utilisation of the treatment.
l The nature of DCEs demands that only a subset of potentially influential factors on clinical decision-making
could be explored in this research. Factors not explored in this study warrant research to understand their
impact, if any, on the decision to offer intravenous thrombolysis. Future work should seek to replicate
these findings and further interrogate the results by considering how interactions may influence
decision-making and explore trade-offs between various factors by including linear attribute. Furthermore,
future research should explore the influence of decision support tools and/or graphical depictions of risk
and benefit for individual patients on clinical decision-making and clinical outcomes.
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Appendix 1 Semistructured schedule for
exploratory interviews regarding decision-making
about thrombolysis
 
Draft of possible questions for semi-structured interview schedule 
Interviewer:  
• Introduce self, background. 
• Describe DCE project, its aims and expected outcomes, purpose of interview, 
and how long the interview should last. Assure participant they can ask for 
clarification on questions or choose not to answer certain questions.  
• Ask permission to audio record interview.  Verbally confirm ethical issues 
around confidentiality, anonymity and right to withdraw/end interview at any 
stage without reason. 
Introduction/clinician background and experience: 
• First, I’d just like to ask you about your experience and background: 
o Can you tell me about your own background? How long have you been 
working in your current position? (education, employment, 
months/years of experience and fields of experience, number of years 
treating acute stroke patients).  
o How long have you been offering thrombolysis where you’re based 
now? 
• How often would you assess acute stroke patients for thrombolysis?  
• Can you tell me, step by step, what is the typical assessment and decision-
making process for thrombolysis that occurs for these patients? 
Understanding clinicians’ decisions to offer intravenous 
thrombolytic tr atment to patien s with acute ischaemic stroke 
- Pilot testing protocol -   
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 Decision-making process and experiences: 
• What clinical and non-clinical factors or resources do you rely upon when 
making decisions about whether to administer thrombolysis for acute 
ischaemic stroke? What are most important in decision-making? 
• What issues create uncertainty for you on whether to offer thrombolysis? How 
do you manage this uncertainty? 
• Do you incorporate patient preferences in your decisions? If yes, how? 
• To what extent do licencing criteria and local or national guidelines influence 
your decision making? 
• To what extent do your colleagues influence your decision making?  
o Do you feel comfortable approaching other clinicians for advice? How 
influential would their recommendation be on your decision? 
• How confident are you in communicating evidence supporting treatments and 
the likely balance of benefit versus harm of treatment with and without 
thrombolysis to patients and families/carers? 
• Could your recent experience with administering thrombolysis and the 
associated patient outcomes influence future decisions? 
• As you’ve gained more clinical experience, how has this influenced your 
decision-making?  
• Are you aware of any debates regarding the use of thrombolysis? 
• What would you regard as particular ‘grey’ areas of decision-making 
regarding administration of thrombolysis?  Can you describe a 
borderline/difficult case regarding the decision to administer thrombolysis 
which you handled? 
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Perceived barriers: 
• Do you perceive any barriers to effective decision-making regarding 
thrombolysis? If so, could you give me examples? 
Other issues: 
• Are there other issues regarding thrombolysis that I haven’t specifically asked 
about or that you would like to mention or highlight as relevant to your 
clinical decision-making about administration of thrombolysis for stroke? 
 
Thank you for your participation in this interview. 
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Appendix 2 Online structured prioritisation
exercise
Thrombolysis decision-making survey 
Thank you for agreeing to take part in this survey, which will be used to inform the design of 
a larger study (funded by the NIHR Health Services and Delivery Research Programme) to 
understand factors influencing clinical decision-making about thrombolysis in the treatment 
of acute ischaemic stroke. We are seeking the views of clinicians involved in making the final 
decision regarding thrombolysis for patients with acute ischaemic stroke. We anticipate that 
completion of this exercise will take no more than 10 minutes. Clinical decision-making 
about thrombolysis takes account of a range of patient-related factors and their interactions. 
We are seeking to understand when various patient-related factors create uncertainty in your 
mind as to whether to offer thrombolysis to patients with acute ischaemic stroke. Data 
obtained from this survey will not be individually assessed or compared with local/national 
guidelines or licencing criteria for thrombolysis. All responses will be strictly confidential. 
With your help, we are hoping to gain insight into the types of scenarios which lead to 
clinical variation in decision-making. Please respond to the questions below in line with your 
own real-world clinical decision-making. If you want to explain your response, please enter 
detail in the free text boxes.  
 
Before providing a response, please carefully read each question in this survey. 
 
Are you a clinician who is responsible for making the final decision about whether or not to 
offer intravenous thrombolysis to eligible acute stroke patients? 
 Yes 
 No 
 
 
<If ‘yes’ is selected, participant may continue to the survey> 
<If ‘no’ is selected, the message below is displayed and survey will skip to end> 
 
Thank you for your interest but unfortunately you do not meet the criteria for participation in 
this study. 
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 Q1. Assuming all other indications point to thrombolysis, at what age(s) or age range(s) 
would you no longer consider it appropriate to offer a patient presenting with acute ischaemic 
stroke intravenous thrombolysis? Please type your answers into the boxes below. 
Highest patient age: (or enter 'none' for no upper age limit) 
____________________
Lowest patient age: (or enter 'none' for no lower age limit) 
____________________
If you would like to provide any further information about your responses to this question, 
please use the text box below: 
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 Q2. Assuming all other indications point to thrombolysis, at what blood pressure levels 
would you no longer think it appropriate to offer intravenous thrombolysis? Please tick once 
in each list; once for systolic blood pressure (BP) and once for diastolic BP. 
 Systolic BP 170-174 mm Hg    
 Systolic BP 175-179 mm Hg 
 Systolic BP 180-184 mm Hg 
 Systolic BP 185-189 mm Hg 
 Systolic BP 190-194 mm Hg 
 Systolic BP 195-199 mm Hg 
 Systolic BP 200-204 mm Hg 
 Systolic BP 205-209 mm Hg 
 No upper limit for systolic blood pressure 
 Diastolic BP 95-99 mm Hg 
 Diastolic BP 100-104 mm Hg 
 Diastolic BP 105-109 mm Hg 
 Diastolic BP 110-114 mm Hg 
 Diastolic BP 115-119 mm Hg 
 Diastolic BP 120-124 mm Hg 
 No upper limit for diastolic blood pressure 
If you would like to provide any further information about your responses to this question, 
please use the text box below: 
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Q3. Would you be willing to control a patient's high blood pressure using medication before 
making the final decision to administer intravenous thrombolysis? 
 Yes 
 No 
 
If yes, up to what level would you be prepared to try and control a patient's blood pressure? 
 
If yes, up to what level would you be prepared to try and control a patient's blood pressure? 
 
________________________________ 
Q4. Assuming all other indications point to thrombolysis, at what NIHSS scores for a 
patient’s current stroke would you no longer think it appropriate to offer intravenous 
thrombolysis? Please tick one lower and one upper value (i.e., one answer per column). 
 0 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
 
 22 
 23 
 24 
 25 
 26 
 27 
 28 
 29 
 30 
 No upper limit for NIHSS (if you believed there may some benefit to the patient) 
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 If you would like to provide any further information about your responses to this question, 
please use the text box below: 
Would your responses for NIHSS score(s) vary according to different patient factors? If yes, 
which one(s)? 
______________________________________________
Q5. Assuming all other indications point to thrombolysis, if an acute ischaemic stroke 
patient is currently taking warfarin, at what international normalisation ratio (INR) level 
would you no longer think it appropriate to offer intravenous thrombolysis? Please tick the 
appropriate cut-off point. 
 1.4
 1.5
 1.6
 1.7
 1.8
 1.9
If you would like to provide any further information about your responses to this question, 
please use the text box below: 
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 Q6. Assuming all other indications point to thrombolysis, at what blood glucose (BM) 
level would you no longer think it appropriate to offer intravenous thrombolysis? Please tick 
as one of the following categories. 
 18.0 – 19.9 mmol/l (324 – 360 mg/dl) 
 20.0 – 21.9 mmol/l (361 – 396mg/dl) 
 22.0 – 23.9 mmol/l (397 – 431 mg/dl) 
 24.0 – 25.9 mmol/l (432 – 468 mg/dl) 
 26.0 – 27.9 mmol/l (469 – 503 mg/dl) 
 No upper limit for blood glucose 
If you would like to provide any further information about your responses to this question, 
please use the text box below: 
Q7. Would you be willing to control a patient’s blood glucose level before making your final 
decision regarding administration of intravenous thrombolysis? 
 Yes 
 No 
If you would like to provide any further information about your responses to this question, 
please use the text box below: 
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 Q8. Assuming all other indications point to thrombolysis, please indicate at what level of 
social support would you no longer think it appropriate to offer intravenous thrombolysis to a 
patient? Please tick one or more categories as appropriate, with reference to the definition in 
the box below.    
 Patient does not have any friends/others/family to help with everyday living or to provide 
emotional/informational support in times of problems/crises 
 Patient has a limited supportive network (a friend or one family member) to help with 
everyday living or to provide emotional/informational support in times of problems/crises 
 Patient has a good supportive network (friends and other people, including family) to help 
with everyday living or to provide emotional/informational support in times of 
problems/crises 
 A patient’s level of social support would not influence my decision to administer 
thrombolysis 
If you would like to provide any further information about your responses to this question, 
please use the text box below: 
Q9. Do you take patient frailty into account when making decisions about thrombolysis for 
patients with acute ischaemic stroke?   
 Yes 
 No 
Social support means that an individual is cared for, has reliable assistance available from 
other people, and is part of a supportive social network. An individual with social support 
resources can access these in everyday living as well as in problem or crisis situations. This 
support can be emotional, tangible (e.g., financial assistance), informational and/or can offer 
companionship. 
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 <If yes, the following two additional questions will appear in survey> 
Please could you describe how you assess patient frailty? 
_________________________________
In what way would patient frailty influence your decision to offer thrombolysis (giving 
examples if possible)? 
_________________________________
Q10. Assuming all other indications point to thrombolysis, at what level of pre-stroke 
cognitive status would you consider inappropriate to offer intravenous thrombolysis to a 
patient with acute ischaemic stroke?  
 Mild cognitive impairment 
 Moderate cognitive impairment 
 Severe cognitive impairment 
 I would not rule out thrombolysis based on a patient’s level of cognitive impairment 
If you would like to provide any further information about your responses to this question, 
please use the text box below: 
 Mild cognitive impairment: Patient experiences increased forgetfulness, slight difficulty 
concentrating, decreased work performance. Patient has difficulty finding the right words.           
Moderate cognitive impairment: Patient experiences difficulty concentrating, decreased memory 
of recent events, and difficulties managing finances or traveling alone to new locations. Patient 
may have trouble completing complex tasks efficiently or accurately and may be in denial about 
their symptoms.           
Severe cognitive impairment: Patient requires extensive assistance to carry out daily activities. 
Patient forgets names of close family members and has little memory of recent events but may 
remember some details of earlier life. Patient has difficulty counting down from 10, finishing 
tasks and the patient’s ability to speak is in decline. 
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 Q11. Assuming all other indications point to thrombolysis, what is the earliest time after a 
laparotomy for a perforated duodenal ulcer that you would consider it appropriate to offer 
thrombolysis? Please tick one category. 
 1 week 
 2 weeks 
 3 weeks 
 1 month 
 2 months 
 ≥ 3 months 
 No time limit would influence my decision 
If you would like to provide any further information about your responses to this question, 
please use the text box below: 
Q12. Assuming all other indications point to thrombolysis, how soon after Percutaneous 
Coronary Intervention (coronary angioplasty and stent insertion) would you consider it 
appropriate to offer intravenous thrombolysis? Please tick one category. 
 1 week 
 2 weeks 
 3 weeks 
 1 month 
 2 months 
 ≥3 months 
 No time limit would influence my decision 
If you would like to provide any further information about your responses to this question, 
please use the text box below: 
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 Q13. Assuming all other indications point to thrombolysis, how soon after a previous 
ischaemic stroke with reference to severity of previous stroke (assessed with NIHSS) would 
you consider it appropriate to offer intravenous thrombolysis? Please tick one timescale for 
each degree of stroke severity (mild, moderate and severe), i.e., one response per column. 
 Previous mild 
stroke (NIHSS <6) 
Previous moderate 
stroke (NIHSS 7-12) 
Previous severe 
stroke (NIHSS ≥13) 
≤1 week       
2 weeks       
3 weeks       
1 month       
2 months       
3 months       
6 months       
>1 year       
Time after previous ischaemic 
stroke would not influence 
my decision to offer 
thrombolysis 
      
More than 6 months but less 
than 1 year       
If you would like to provide any further information about your responses to this question, 
please use the text box below: 
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Debriefing 
 
Many thanks for your participation in this survey that will be used to identify 
influential factors in clinical decision-making regarding the administration of 
thrombolysis for patients with acute ischaemic stroke.      
 
To submit your answer, please click the blue button below.     
 
If you have any further questions about this exercise, please contact the lead 
researcher using the contact details below.   
 
 
[contact details included here] 
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Appendix 3 Pilot testing protocol
Guidelines for interviewer:
l Review questionnaire, determine appropriate probes for questions, list additional probes to encourage
participants to engage in ‘thinking aloud’.
l Before you begin interview/testing, explain process of interview to participant, using examples and
exercises to communicate meaning of approach, i.e. how it operates in practice.
Script to guide interview:
l Thank participant for taking part and for their time.
l Briefly describe the aims and purpose of the research and why this pilot testing phase is important.
l Explain how this testing differs from traditional interview/survey testing:
During this interview, you will be working your way through the online survey. However, this process
differs from a typical interview or a survey testing session, as I’d like you to read instructions and questions
aloud as you go, as well as think aloud, reporting your interpretations and reactions to questions, as well
as what details and information you consider in reaching your answer to a question. Our goal with this
approach is to get a better idea of how the questions are working and are being interpreted and this will
help us to ensure there are not problems around questions being misleading, too vague or confusing.
So, by speaking aloud your thought processes during the survey, we’ll be able to assess this. For this
testing, we are not so much interested in your answer but rather your understanding of the questions and
situations described and how you react and think through information to reach an answer.
At times I may stop and ask you more questions about certain questions or items and I may take
occasional notes. Also, with your permission, it would be helpful to audio record the testing session.
Please keep in mind that I want to hear all of your opinions and reactions. Don’t hesitate to mention if a
question is unclear or problematic for whatever reason.
Finally, the online survey should take no longer than 60 minutes to complete. Do you have any questions
before we start?
Think-aloud practice exercise
To give you an idea of what the approach is like and help you adapt to it, we’ll just start with an example.
I’ll go first with this one and then you can have a go.
l How many windows are in your house or apartment?
l How did you go about coming up with that answer?
l How difficult was it to arrive at that answer?
Ask if there are any final questions before beginning survey. Remind participant again to think aloud and
that interviewer will stay mostly silent during testing.
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List of general probes:
l In your own words, what is this question asking?
l What does the term ‘x’ mean to you?
l What do you consider when answering this question?
l How did you arrive at your answer?
l What did you consider in reaching your answer?
l What time period did you consider in arriving at your answer?
l When you’re asked about average, how did you arrive at an approximate rate? How difficult is this
question to answer in terms of this question?
l What made you hesitate in giving your answer?
l Can you repeat what you’ve just read in your own words?
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Appendix 4 Full online discrete choice
experiment survey
 
Thank you for your interest in taking part in this study which is investigating factors that 
influence clinical decision-making about treating patients with acute ischaemic stroke with 
intravenous thrombolysis. The study is funded by the NIHR Health Service and Delivery 
Research Programme and is led by researchers from Newcastle University. 
If you decide to take part in this survey, then you will be asked to complete (i) a series of 
background questions about your clinical experience; and (ii) two short scales relating to risk 
and uncertainty. You will then be presented with a number of vignettes, which describe 
hypothetical patients with acute ischaemic stroke. Based on the information provided, you 
will be asked whether or not you would offer intravenous thrombolysis to the patient. 
We anticipate the full survey will take between 30-45 minutes to complete. You will be able 
to save and return to the survey at a later date, if required. 
This survey is not a test or an assessment of your clinical decision-making. The responses 
provided will not be judged in accordance with current licensing criteria or local/national 
guidelines for thrombolysis. We are interested in real-world decision-making. All responses 
will remain strictly confidential and your name or other personal details will not appear in 
any report or publication arising from this research. 
Completion of the survey and submission of responses provides your consent to take part in 
the study. The information and answers you provide will be electronically stored on the 
secure server of Accent (http://www.accent-mr.com/) the firm hosting the online survey. By 
ticking the box below and continuing to the survey, you are indicating your agreement with 
the following:  
• I have read the information about this survey.  
• I understand that I am free to withdraw my participation at any point during the survey. 
• I understand that participation in the survey is completely voluntary. 
• I understand that responses I provide to the survey will be combined with those provided 
by other participants and will be statistically analysed for presentation in published 
reports and peer review articles, and that no personally identifiable information about me 
will appear in any report or article.  
 
Please click the relevant box below to indicate your agreement and to progress to the survey: 
 I agree to participate in this study 
 I do not agree to participate in this study 
If you have any questions about the research, please contact: [contact details here] 
DOI: 10.3310/hsdr05040 HEALTH SERVICES AND DELIVERY RESEARCH 2017 VOL. 5 NO. 4
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Thomson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
85
 Are you a clinician who is responsible for making the final decision about whether or 
not to offer intravenous thrombolysis to eligible acute stroke patients? 
[  ] Yes 
[  ] No  
If Yes, participants may progress to survey (next page: Email entry page to generate 
unique survey link). 
If No, participants are screened out of survey and presented with the following message: 
Thank you for your interest but unfortunately you do not meet the criteria for participation in 
this study. 
Page after email entry: 
Thank you. A message has been sent to the email address which contains your own unique 
link to the survey. Please note that your responses will not be associated with your email 
address and your answers will remain anonymous. 
Would you like to complete the survey now?  
Please note that if you choose ‘Yes’, you will be re-directed to your own unique web link. If 
you choose ‘No’, you can still complete the survey at a later stage by going into the email 
sent to your email address.  
 Yes (please redirect me to my personal survey link) 
 No (I will complete the survey at a later date) 
Thank you. 
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 Demographics and Experience  
Q1. Please state your gender by ticking the appropriate box below. 
[  ] Female 
[  ] Male 
Q2. Please state your age in the box below. 
years 
Q3. Please indicate below the option that best represents your medical speciality in relation to 
stroke care. 
[  ] Stroke physician 
[  ] Accident & Emergency specialist 
[  ] Acute care physician 
[  ] Geriatric medicine physician 
[  ] Neurologist 
[  ] Other (please specify): ___________________ 
Q4. In the box below, please indicate your grade/level of seniority. 
[  ] Consultant
[  ] Staff doctor 
[  ] Speciality trainee 
[  ] Other (please specify): ___________________ 
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Q5. How many months/years of experience do you have in treating acute ischaemic stroke 
patients? 
 
____________ months 
 
____________ years 
 
 
Q6. How many months/years of experience do you have in administering intravenous 
thrombolysis to acute ischaemic stroke patients? 
 
____________ months 
 
____________ years  
 
 
Q6a. Would you be willing to control a patient's high blood pressure using medication before 
making the final decision to administer intravenous thrombolysis? 
 [  ] Yes 
 [  ] No   
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Patient vignettes 
 
Introduction to task 
 
In the following screens, you will be presented with 13 vignettes, which will describe 
hypothetical patients presenting with acute ischaemic stroke. You will be asked if you would 
or would not offer intravenous thrombolysis in the standard licensed dose, based on the 
information provided in the vignette. 
 
For the purposes of this task you should assume that:  
• Either patient consent or family assent for treatment will be available,  
• A thrombolysis bolus can be prepared within five minutes, and  
• All patients described are right-handed. 
The following variables will be 'fixed'; i.e., the factor will be exactly the same in each patient 
vignette:  
• Blood glucose level of 6 mmol/L  
• CT scan result that is consistent with ischaemic stroke and showing no haemorrhage 
or new ischaemic changes  
• The patient is not on anticoagulation therapy  
• The patient has no recent history of significant bleeding  
• The patient has no history of diabetes 
In contrast, the following factors will vary across the vignettes:  
• Patient demographics  
• NIHSS score  
• Frailty  
• Pre-stroke dependency (mRS)  
• Pre-stroke cognitive status  
• Symptom onset time  
• Systolic blood pressure 
A blue information icon will provide further information or a definition for certain terms in 
the vignettes. Hovering the cursor over this icon will reveal the text. 
 
It is important that your answers are based on your real-world decision making. 
 
Please note that in all patient vignettes that will be presented to you, the patient has suffered 
an acute ischaemic stroke. We are asking whether or not you would immediately offer 
thrombolysis to each patient, based on their current status. 
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 Vignette structure 
A [68; 85; 95] year old [white; Afro-Caribbean; Asian] [man ; woman] has been admitted to 
hospital with acute ischaemic stroke. Symptom onset began [50 minutes ; 2 hours 30 
minutes; 4 hours 15 minutes] ago. The patient, [who you perceive as frail; who you do not 
perceive as frail], had a pre-stroke dependency mRS of [1; 3; 4]. Further investigation 
revealed the patient is not on anticoagulation therapy and has a blood glucose level of 6 
mmol/L. The patient has [no history of; moderate; severe] dementia and at the time of the 
treatment decision, the patient’s systolic blood pressure is [140; 185; 200]mmHg. The patient 
has no recent history of significant bleeding and no history of diabetes. Clinical assessment of 
stroke severity indicated a NIHSS score of [2 (with aphasia); 2 (without aphasia); 5 (with 
aphasia); 5 (without aphasia); 14 (without aphasia); 23 (without aphasia)]. A CT scan was 
conducted and is consistent with ischaemic stroke; it shows no haemorrhage or new 
ischaemic changes.  There are no other factors which would deter treatment. 
Given the information presented above would you immediately offer thrombolysis to this 
patient? 
[  ] Yes 
[  ] No 
Do you have any comments about this case? If so, please enter your comments in the text 
bow below. If you do not have any comments, please tick 'No' below. 
[  ] No 
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If participant answers ‘yes’ to Q1 (“Would you immediately offer thrombolysis to this 
patient?”), they will be asked if they have any comments about this case (free text response, 
as it currently is) and will progress to the next vignette.  
 
However, if participant answers ‘no’ to Q1 (“Would you immediately offer thrombolysis to 
this patient?”), Q2 should appear below the text box ideally only for those vignettes when the 
blood pressure is 185 or 200.  
 
Q2. Would you attempt to lower the patient’s blood pressure before reassessing the patient’s 
suitability for intravenous thrombolysis? 
[  ] Yes 
[  ] No 
 
If participant answer ‘no’ to Q2, they progress to the next vignette. If participant answers 
‘yes’ to Q2, Q3 will appear: 
 
Q3. Assuming all other patient factors remain the same, at what level of lowered systolic 
blood pressure would you be prepared to treat this patient with intravenous thrombolysis? 
Please tick the highest value of systolic blood pressure at which you would treat this 
patient. 
 
___________ mmHg 
DOI: 10.3310/hsdr05040 HEALTH SERVICES AND DELIVERY RESEARCH 2017 VOL. 5 NO. 4
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Thomson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
91
Service structure and delivery 
 
Q7. Please indicate the regional strategic clinical network (SCN) in which you work. 
[  ] Cheshire and Mersey SCN 
[  ] East Midlands SCN 
[  ] East of England SCN 
[  ] Islands  
[  ] London SCN 
[  ] Manchester, Lancashire & S.Cumbria SCN 
[  ] North of England SCN 
[  ] Northern Ireland 
[  ] Scotland 
[  ] South East Coast SCN 
[  ] South West SCN 
[  ] Thames Valley SCN 
[  ] Wales 
[  ] Wessex SCN 
[  ] West Midlands SCN 
[  ] Yorkshire and The Humber SCN 
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Q8. Please enter the name of the hospital where you are principally based. This will help us 
link characteristics of service structure to project findings.  [Please note that this information 
will only be used to link characteristics of service/institutional structure with your responses 
and individual-level data will not be associated with specific hospitals or treatment centres. 
Data you report will be combined with responses of others and analysed and presented in 
aggregated form] 
 
___________________________ 
 
 
Q8(a). In the space below, please report the approximate percentage of stroke patients 
thrombolysed in the hospital in which you are principally based. 
 
__________________________ 
 
 
Q8(b).  Please tick below the description that best represents the service configuration of your 
place of work.  
 [  ] Consultant-led services in all cases (consultants present on-site and lead all decisions 
about thrombolysis)  
[  ] Telemedicine services only 
[  ] Combination of consultant-led services and telemedicine services  
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Q9. To help provide insight into the type of hospital in which you primarily work, please 
indicate your agreement with the following statements in the table below. When considering 
these statements, please respond in relation to the team involved in thrombolysis decision-
making in the treatment of acute ischaemic stroke in the hospital in which you are principally 
based. 
 
 
Item: 
Strongly 
disagree   
1 
Moderately 
disagree  
2 
Slightly 
disagree 
3 
Slightly 
agree       
4 
Moderately 
agree     
5 
Strongly 
agree     
 6 
Most people whose opinion I value 
would approve of me treating a patient 
presenting with acute ischaemic stroke 
within a 4.5 hour time window with 
intravenous thrombolysis 
      
Prior to delivery of intravenous 
thrombolysis, clinicians are provided 
with adequate training to inform 
decision-making regarding the 
appropriate use of intravenous 
thrombolysis in the treatment of 
patients with acute ischaemic stroke 
      
We encourage internal discussion of 
patient care adverse events 
      
There is an identifiable practice style 
that we all try to adhere to 
      
My hospital strongly encourages me to 
thrombolyse patients who meet criteria 
for intravenous thrombolysis when 
presenting with acute ischaemic stroke 
      
My hospital does not hold meetings 
regularly to discuss and review stroke 
service audit data 
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Q10. In the following set of statements, we are interested in understanding your approach to 
risks and risk-taking in general. Please think about each statement and indicate on the scale 
below your level of agreement or disagreement.  
 
 
Item: 
Strongly 
disagree 
1 
Moderately 
disagree  
2 
Slightly 
disagree 
3 
Slightly 
agree 
4 
Moderately 
agree    
 5 
Strongly 
agree 
6 
I enjoy taking risks       
I try to avoid situations that have 
uncertain outcomes 
      
Taking risks does not bother me if 
the gains involved are high 
      
I consider security an important 
element in every aspect of my life 
      
People have told me that I seem to 
enjoy taking chances 
      
I rarely, if ever, take risks when 
there is another alternative 
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Q11. In the following set of statements, we are interested in understanding how you deal with 
uncertainty in your clinical practice regarding acute stroke care / decision making about 
thrombolysis. Please think about each statement and indicate on the scale below your level of 
agreement or disagreement. 
 
Item: 
Strongly 
disagree 
1 
Moderately 
disagree  
2 
Slightly 
disagree 
3 
Slightly 
agree 
4 
Moderately 
agree   
 5 
Strongly 
agree 
6 
I usually feel anxious when I am not 
sure of a diagnosis. 
      
I find the uncertainty involved in 
patient care disconcerting. 
      
Uncertainty in patient care makes me 
uneasy. 
      
I am quite comfortable with the 
uncertainty in patient care.  
      
The uncertainty of patient care often 
troubles me 
      
When I am uncertain of a diagnosis, I 
imagine all sorts of bad scenarios—
patient dies, patient sues, etc. 
      
I fear being held accountable for the 
limits of my knowledge. 
      
I worry about malpractice when I do 
not know a patient's diagnosis. 
      
When physicians are uncertain of a 
diagnosis, they should share this 
information with their patients  
      
I always share my uncertainty with 
my patients  
      
If I shared all of my uncertainties 
with my patients, they would lose 
confidence in me 
      
Sharing my uncertainty improves my 
relationship with my patients  
      
I prefer patients not know when I am 
uncertain of what treatments to use. 
      
I almost never tell other physicians 
about diagnoses I have missed. 
      
I never tell other physicians about 
patient care mistakes I have made. 
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Q12. How recently did you last make a decision about whether to treat or not treat an acute 
ischaemic stroke patient with thrombolysis? Please report your answer using number of days, 
weeks, and/or months below. 
_________ days    __________weeks    ________months 
 
 
Q13. Approximately, how many acute stroke patients have you thrombolysed over the past 
12 months?  
___________  
 
 
Q14. Typically, out of every 100 acute stroke patients you assess for eligibility for 
intravenous thrombolysis, approximately how many would you thrombolyse?  
 
________ out of every 100 
 
 
Q15a. In the past 12 months, how many instances where you have administered intravenous 
thrombolysis to a patient presenting with acute ischaemic stroke have resulted in the patient 
being harmed as a result of treatment? 
 
____________
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Q15b. How recent was your last experience of a harmful effect of intravenous thrombolysis 
treatment on a patient presenting with acute ischaemic stroke? Please report your answer 
using number of days, weeks and/or months below. 
 
_________ days    __________weeks    ________months 
 
Q16. Does your work place have a formal acute stroke protocol for assessing patient 
eligibility for thrombolytic treatment?  
[  ] Yes 
[  ] No 
[  ] Don’t know 
If ‘yes’ to last question, the flowing questions (Q16b) should appear: 
 
 
Q16(b). If you answered ‘yes’ to Q16, are there circumstances where you do not strictly 
adhere to the protocol? 
[  ] Yes 
[  ] No 
If yes, please elaborate on the circumstances where you would not strictly adhere to the 
protocol: 
____________________________________________ 
 
 
Q17. On a scale from 1–6, where 1 indicates ‘not at all comfortable’ and 6 indicates ‘very 
comfortable’, please indicate your level of comfort when: 
(i) treating a patient with acute ischaemic stroke with intravenous thrombolysis outwith the 
licencing criteria: 
  [  ]                     [  ]                      [  ]                        [  ]                        [  ]                           [  ]                
   1                        2                         3                          4                          5                             6                  
Not at all                  Very        
comfortable        comfortable               
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(ii) not treating a patient with acute ischaemic stroke with  intravenous thrombolysis who is 
within the licencing criteria for treatment: 
     [  ]                      [  ]                      [  ]                       [  ]                       [  ]                       [  ]                
      1                         2                         3                         4                          5                         6                 
Not at all                           Very       
comfortable                                        comfortable 
  
 
Q18. On a scale from 1–6, where 1 indicates ‘strongly disagree’ and 6 indicates ‘strongly 
agree’, please indicate your agreement with the following statement: 
I am very confident in communicating the potential risks and benefits of thrombolysis to 
patients or their family/carers. 
   [  ]                      [  ]                       [  ]                      [  ]                        [  ]                      [  ]                
    1                         2                          3                        4                           5                         6                   
Strongly                 Strongly         
disagree                                             agree 
 
 
Q19. On a scale from 1–6, where 1 indicates ‘strongly disagree’ and 6 indicates ‘strongly 
agree’, please indicate your agreement with the following statement: 
I believe the evidence is robust for treating acute ischaemic stroke with intravenous 
thrombolysis when a patient presents within a 4.5 hour time window and there are no other 
contraindications for treatment. 
    [  ]                      [  ]                       [  ]                      [  ]                       [  ]                        [  ]                
     1                         2                          3                        4                          5                           6                   
Strongly                   Strongly         
disagree                                   agree 
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Debriefing 
Thank you for your participation in this study, which will help to identify the most influential 
factors in clinical decision-making regarding the administration of thrombolysis for patients 
with acute ischemic stroke, including the nature of the trade-offs made between these factors 
(and associated levels). 
The information and answers you provided will be compiled with those of other respondents 
and will be analysed as part of a larger data set. We expect that the results from this study 
will be available in early 2015 and will be disseminated in peer-review publications and via 
national conference presentations. When the published results are available, we will circulate 
a summary of the findings and a link to the full report/paper via the mailing list used to 
contact you about this research. 
If you would like to be entered into an optional prize draw to win an iPad, please enter you 
email address in the box below. (Please note that email addresses provided here will not be 
associated with previous responses given, but will be stored in a separate file). The winner 
will be selected at random by the research team at the Institute of Health & Society, 
Newcastle University when the survey closes. 
Optional entry of your email  
address for prize draw: 
If you have any further questions about this research, please contact the lead researcher using 
the contact details below. We recommend that you print this page for your own records in the 
event that you wish to contact a member of the research team at a later date.
[contact details here] 
- END OF SURVEY - 
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Appendix 5 Factor analysis of Institutional
Culture Scale
Factor analysis using principal component analysis (PCA) with orthogonal rotation (varimax) was conductedon the six-item scale. The Kaiser–Meyer–Olkin (KMO) measure verified the sampling adequacy for the
analysis, KMO = 0.83, which suggests that the sample size is adequate for factor analysis.132 Bartlett’s test of
sphericity [χ2(15)= 338.95; p < 0.001] indicated that correlations between items were sufficiently large for
PCA. An initial analysis was run to obtain eigenvalues for each component in the data. The results indicated
that only one component had an eigenvalue of > 1 and explained 57.47% of the variance. Following
inspection of the scree plot, the one component was confirmed and retained for the final analysis. Table 16
displays the factor loadings after varimax rotation. Factor loadings of > 0.55 are considered ‘good’ to
‘excellent’.133 The one-component solution suggests that the items on the scale all measure institutional
culture of thrombolysis. Reliability analysis was conducted and internal consistency was high, with Cronbach’s
alpha of 0.84.
TABLE 16 Rotated factor loadings for Institutional Culture Scale
Items
Rotated factor
loadings
Most people whose opinion I value would approve of me treating a patient presenting with acute
ischaemic stroke within the 4.5-hour time window with intravenous thrombolysis
0.78
Prior to delivery of intravenous thrombolysis, clinicians are provided with adequate training to inform
decision-making regarding the appropriate use of intravenous thrombolysis in the treatment of patients
with acute ischaemic stroke
0.79
We encourage internal discussion of patient care adverse events 0.84
There is an identifiable practice style that we all try to adhere to 0.74
My unit strongly encourages me to thrombolyse patients who meet criteria for intravenous thrombolysis
when presenting with acute ischaemic stroke
0.83
My unit does not hold meetings regularly to discuss and review stroke service audit dataa 0.52
Scale reliability (α) 0.84
a Item is reverse scored.
DOI: 10.3310/hsdr05040 HEALTH SERVICES AND DELIVERY RESEARCH 2017 VOL. 5 NO. 4
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Thomson et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
101

Appendix 6 Further information on discrete
choice experiment design and analysis
The DCE approach follows random utility theory, in which an individual, n, is assumed to choose theutility-maximising option i when presented with a choice set, Cn, containing alternative
scenarios following:
Uin = v + εin= α + βXin + εin, (1)
where v is the systematic component, α refers to the ASC, β is related to the vector of coefficients, X is the
vector of k attributes and εin relates to the random component (unobservable variation). A respondent is
assumed to choose the scenario j among alternatives J if the utility derived from that alternative is greater
than the utility from any other alternative in the choice set.
The model will estimate the probability of a chosen alternative, j, as a function of the attributes k. In the
current study, the utility derived from the chosen option is described by:
UOffer–of–thrombolysis = α + β1–Age + β2–Sex + β3–Ethnicity + β4–Symptom–onset–time + β5–Frailty
+β6–Prestroke–dependency + β7–Prestroke–Cognitive–status + β8–SystolicBP
+β9–NIHSS–score + ε:
(2)
Further details on discrete choice experiment analysis
The initial analysis employed the benchmark case of a conditional logit model (or clogit) which is based
on three assumptions: (1) independence of irrelevant alternatives; (2) error terms are independent and
identically distributed across observations; and (3) no preference heterogeneity (i.e. identical preferences
across respondents). Alternative model specifications were also tested, including mixed logit and
generalised multinomial logit models. Goodness-of-fit criteria, including Akaike and Bayesian information
criteria, were used to determine the best model for the data.
Based on the data analysis plan, the objectives of the research, results of preliminary analyses, and Akaike
and Baysian goodness-of-fit criteria, the mixed-effects logistic regression was deemed most appropriate.
Mixed-logit regression models were optimal as they allow for the examination of unobserved preference
heterogeneity: that is varying model estimates across individuals. Mixed-logit regression facilitated the
examination of heterogeneity among respondents (which was expected) and relaxed the assumption of
independence from irrelevant alternatives, which is an underlying assumption of the clogit model. The
mixed-logit regression allowed for increased flexibility by specifying certain coefficients to be randomly
distributed across individuals. Estimation by maximum simulated likelihood was undertaken using the
user-written ‘mixlogit’ Stata programme (Arne Hole, Boston College Department of Economics, Boston,
MA, USA). All estimation results reported were generated assuming the random parameters were normally
distributed and using 250 Halton draws to simulate the likelihood functions to be maximised. There is an
inherent trade-off between the number of Halton draws and the time taken to compute various models. It is
suggested that an analysis build up models working from the default of 50, up to 100, 200, 250, 500 and
up to 1000, if appropriate. However, given the number of random effects specified in the current study, it was
not feasible to compute models with 500 or 1000 Halton draws and therefore 250 was set for each model.
Effects coding was used for the analysis. This refers to a way of using categorical predictor variables in
estimation models. It is similar to dummy coding but uses ones, zeros and minus ones to represent
information on factor levels. Effects coding facilitates reliable estimates of main effects and interaction
effects (if included/required) and allows for estimation of all levels.134
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Appendix 7 Model 3: summary of mixed-effects
logistic regression results
T able 17 displays the results of the analysis when all clinician variables are added as predictors tothe model.
TABLE 17 Model 3: summary of mixed-effects logistic regression influence of patient factors/levels and clinician
factors on the decision to offer intravenous thrombolysis
Factor Level Coefficient SE p-value Odds ratio (95% CI)
Patient age,
mean (SD)
68 Reference
85 1.3 (1.54) 0.57 (0.57) 0.02 (0.01) 3.67 (1.21 to 11.15)
95 –1.65 (0.15) 1.15 (0.43) 0.15 (0.01) 0.19 (0.02 to 1.27)
Patient ethnicity,
mean (SD)
White Reference
Asian –0.81 (2.64) 0.53 (0.82) 0.13 (0.001) 0.45 (0.16 to 1.27)
Afro-Caribbean 2.66 (0.03) 0.97 (0.41) 0.006 (0.94) 14.34 (2.15 to 95.5)
Patient sex,
mean (SD)
Male Reference
Female 1.1 (0.23) 0.98 (0.31) 0.26 (0.46) 3.0 (0.44 to 20.49)
Time since symptom
onset, mean (SD)
50 minutes Reference
2 hours 30 minutes 2.01 (2.2) 0.71 (0.61) 0.005 (< 0.001) 7.48 (1.86 to 30.15)
4 hours 15 minutes –3.27 (2.04) 0.89 (0.54) < 0.001 (< 0.001) 0.04 (0.01 to 0.22)
Patient frailty,
mean (SD)
Not frail Reference
Frail –0.49 (0.1) 0.39 (0.28) 0.21 (0.72) 0.61 (0.28 to 1.3)
Pre-stroke
dependency (mRS
score), mean (SD)
mRS1 1.86 (3.77) 1.74 (1.13) 0.28 (0.001) 6.42 (0.2 to 192.5)
mRS3 0.97 (2.69) 0.55 (0.58) 0.08 (< 0.001) 2.65 (0.91 to 7.74)
mRS4 Reference
Pre-stroke cognitive
status, mean (SD)
No history of
memory problems
Reference
Moderate dementia 0.87 (2.43) 0.5 (0.72) 0.08 (0.001) 2.39 (0.91 to 6.33)
Severe dementia –3.81 (2.2) 1.14 (0.66) 0.001 (0.001) 0.02 (0 to 0.21)
SBP, mean (SD) 140 mmHg Reference
185 mmHg 3.06 (2.5) 0.88 (0.74) 0.001 (0.001) 21.24 (3.77 to 119.7)
200 mmHg –9.89 (3.94) 2.21 (0.94) < 0.001 (< 0.001) 0 (0 to 0)
NIHSS score (stroke
severity), mean (SD)
2 (without aphasia) Reference
2 (with aphasia) –0.83 (2.85) 0.89 (0.89) 0.35 (0.001) 0.44 (0.08 to 2.48)
5 (without aphasia) 3.24 (0.95) 1.13 (0.77) 0.004 (0.22) 25.41 (2.79 to 231.6)
5 (with aphasia) 2.3 (7.53) 0.91 (1.92) 0.01 (< 0.001) 9.92 (1.68 to 58.79)
14 5.38 (0.71) 1.63 (0.7) 0.001 (0.32) 216.2 (8.8 to 5318)
23 5.21 (1.5) 1.67 (0.73) 0.002 (0.04) 182.5 (6.9 to 4793)
continued
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TABLE 17 Model 3: summary of mixed-effects logistic regression influence of patient factors/levels and clinician
factors on the decision to offer intravenous thrombolysis (continued )
Factor Level Coefficient SE p-value Odds ratio (95% CI)
Perception of
evidence base
0.55 0.29 0.056 1.73 (0.99 to 3.03)
Number
thrombolysed in
past 12 months
0.11 0.03 < 0.001 1.11 (1.05 to 1.18)
Physician reaction
to uncertainty
0.02 0.68 0.97 1.02 (0.27 to 3.83)
Attitude towards
risk
–0.03 0.07 0.67 0.97 (0.85 to 1.11)
Number harmed by
thrombolysis in past
12 months
–0.45 0.45 0.32 0.64 (0.26 to 1.55)
Days since patient
was harmed by
thrombolysis
–0.001 0.001 0.31 1 (1 to 1)
Comfort treating
outside criteria
–0.53 0.23 0.02 0.59 (0.38 to 0.93)
Experience
administering
thrombolysis
(months)
–0.01 0.01 0.26 0.99 (0.97 to 1.01)
Medical specialty
(all compared
stroke clinician)
1.05 0.75 0.16 2.85 (0.65 to 12.4)
Perception of
institutional culture
0.01 0.04 0.9 1.06 (0.9 to 1.11)
Service
configuration
of hospital
(combination
telemed and
consultant led
compared with
consultant led only)
2.82 1.06 0.01 16.78 (2.1 to 133.9)
Confidence
communicating
risk information
–0.24 0.34 0.47 0.78 (0.4 to 1.52)
Recency of last tPA
decision
–0.01 0.01 0.61 0.99 (0.81 to 1.01)
Location: Midlands 2.65 1.13 0.02 14.1 (1.5 to 128.5)
Location: South 2.99 1.16 0.01 20.1 (2.1 to 193.3)
Location:
London/Thames
2.55 1.13 0.02 12.76 (1.4 to 116.8)
Location: Northern
Ireland
–12.39 3.45 < 0.001 0 (0 to 0)
Location: Scotland 6.19 2.01 0.002 488.8 (9.5 to 25034)
Location: Wales 3.95 1.55 0.01 51.8 (2.5 to 1083)
Location: Islands –0.94 2.3 0.68 0.39 (0 to 34.8)
Clinician age 0.08 0.04 0.046 1.08 (1 to 1.2)
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TABLE 17 Model 3: summary of mixed-effects logistic regression influence of patient factors/levels and clinician
factors on the decision to offer intravenous thrombolysis (continued )
Factor Level Coefficient SE p-value Odds ratio (95% CI)
Clinician sex
(female)
1.15 0.81 0.16 3.14 (0.6 to 15.3)
ASC, mean (SD) Decision to offer
thrombolysis
–19.03 5.27 < 0.001
Block effects, mean Block 3 5.38 1.73 < 0.01
Block 7 2.84 1.26 0.02
Block 8 3.3 1.42 0.02
SD, standard deviation.
Log-likelihood = –576.29; likelihood ratio χ2(20)= 186.32; number of observations = 1583; 24 observations removed by
Stata for not contributing significantly to the model estimates. These observations related to individuals with little or no
variation in their decision-making, i.e. answered in one way (i.e. to treat/not treat) in all or all but one case.
Akaike information criteria: 1252.57; Bayesian information criteria: 1520.93.
Seven dummy variables were included in the model to control to possible block effects. The effects (vs. block 1) that
emerged as significant are reported above. All other effects were not significant (all p-values > 0.05).
Location variables compared with clinicians based in north of England.
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Appendix 8 Predicted probabilities of offering
thrombolysis
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